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Abstract
Implanted medical devices undergo complications the longer they remain in contact
with tissue or blood. This rejection of foreign materials by our body is one of the largest
reasons innovations in biomedical sensors and implanted technology are being held
back. One means to hold off this unwanted response is through the utilization of nitric
oxide (NO) releasing materials. Two unique NO releasing polymeric materials were
synthesized and characterized before being implanted subcutaneously. Both NO
releasing materials described used S-nitrosothiol (RSNO) chemistry as the main
mechanism for NO release. The first material described covalently links an RSNO to
the backbone of PVC while the second material has RSNOs covalently attached to a
hyperbranched polyamidoamine (HPAMAM) molecule, which is then blended within a
polymer matrix. A high reservoir of NO was observed in the NO releasing HPAMAM
when compared to other NO releasing polymers.
The two materials (SNAP-PVC, SNAP-HPAMAM blended in PVC) were implanted
subcutaneously and were tested versus control polymers that did not release NO;
materials were explanted after 1 and 15 days and histological characterization was
completed. The inflammatory response was then observed through histological analysis
and NO demonstrated anti-inflammatory properties, specifically by observing the
presence of cells marked with CD11b, CD163, and iNOS. Fibrosis was also a major
inflammatory response carefully observed. NO releasing implants showed a much more
resolved state of inflammation and wound healing while the controls demonstrated
signs of chronic inflammation and increased number of pro-inflammatory cells. The
long lasting SNAP-HPAMAM PVC NO releasing materials showed a large reduction in
chronic inflammatory macrophages marked with iNOS with a slight upregulation in
anti-inflammatory macrophages after 15 days of implantation. Compared to control
PVC implants, a significant reduction in fibrosis was observed as the encapsulation
thickness was 120.28±36.1 µm while SNAP-PVC was 74.20±29.9 µm and SNAPHPAMAM was 38.68±21.0 µm. A trend was seen in the reduction of CD11b+ cells with
xv

an increase in NO from the implants, along with an increasing trend of CD163+ cells.
The presence of chronic inflammatory iNOS cells was also greatly reduced with the
increase of NO to the surrounding subcutaneous tissue.

xvi

Chapter 1 : Introduction
1.1 Discovery and Background of Nitric Oxide
1.1.1 Background of nitric oxide
The first role of nitric oxide (NO) as an important signaling molecule was initially
demonstrated by Ferid Murad in 19771. Murad and his colleagues investigated the
impact NO had on enzyme regulatory functions within the body- specifically with
guanylate cyclase (sGC) and the formation of cyclic guanosine monophosphate
(cGMP). Once this mechanism of activation was clarified, the role of cGMP was then
studied more closely. They investigated the role of nitrite containing compounds within
various organs of the body and observed vascular relaxation and NO were closely
associated, but did not exactly understand the mechanism that was responsible for this
phenomenon1-2. The discovery of endothelial cells impact on controlling the relaxation
of smooth muscle cells through acetylcholine was then proven by Robert F. Furchgott,
bringing up the role of endothelial derived relaxation factor (EDRF) within vascular
endothelial cells3. The identity of this unknown vasorelaxation function was then
proven to be NO in 1986 when he and Louis J. Ignarro along with other colleagues
proved that the EDRF that was causing smooth muscle cell relaxation was actually NO45

. Identifying this important pathway brought up a multitude of other questions of its

function in various places throughout the body. Virtually every mammalian cell in the
body is influenced in some way by NO as this highly reactive free radical molecule
plays an important role in cell signaling.
1.1.2 Nitric oxide’s function in the body
The production of NO is accomplished through specific enzymatic pathways based on
three different isoforms depending on the location in the body: endothelial nitric oxide
synthase (eNOS), neuronal nitric oxide synthase (nNOS), and inducible nitric oxide
1

synthase (iNOS). These enzymes produce NO by catalyzing the reaction of L-arginine
and nicotinamide adenine dinucleotide phosphate (NADPH) to form L-citrulline and
NO6-7. eNOS and nNOS are labeled as constitutive NOS as they are calcium-calmodulin
dependent pathways. Healthy vasculature requires the production of NO through eNOS
within endothelial cells8-9. Under normal conditions, NO is constantly produced by
eNOS within blood vessels. Stimulation of NO synthesis begins either through shear
stress caused by blood flow along the endothelial lining or by endothelial receptors
specific to certain ligands which stimulate calcium release within the cell to eventually
activates eNOS10 (Figure 1.1). NO produced diffuses into the smooth muscle cell layer
to activate the enzyme sGC. sGC is then modified into cGMP, which is an important
factor for causing smooth muscle cell relaxation and vasodilation within blood
vessels11. NO is also released into the bloodstream where it interacts with platelets,
contributing to the non-adhesive properties to vasculature through the same sGC-cGMP
pathway seen in smooth muscle cells12-13. If NO production is impaired in the
endothelium, the risk for atherosclerosis and hypertension drastically increase. Neuronal
cell signaling is the primary function of NO production through nNOS (Figure 1.2).
The presence of NO was discovered in numerous neural systems in the body, which
regulate the release of certain neurotransmitters such as the increase in production of
acetylcholine14, 15. iNOS is the one isoform that is not dependent on the calciumcalmodulin pathway that eNOS and nNOS require. This is due to the fact that the
calmodulin is more tightly bound when compared to the other enzymes, and is unable to
react as readily with calcium ions16. Macrophages are the main producer of iNOS, and
are activated in the presence of certain cytokines and bacteria17 (Figure 1.3). It is a
strong mediator of inflammatory response and regulating the immune system. The NO
produced in this pathway is used to destroy foreign bacteria as NO forms peroxynitrites
(ONOO-) in the presence of radical oxygen species (ROSs), a highly damaging product
to cellular structures18.

2

Figure 1.1. Mechanism for the production of NO from eNOS within endothelial cells.
Acetylcholine and/or shear stress causes the upregulation of calcium ions within
endothelial cells, which leads to the conversion of L-arginine to L-citrulline and NO
facilitated by eNOS. NO then diffuses into the bloodstream where it causes platelet
deactivation and into the smooth muscle layer where vasorelaxation occurs.

3

acetylcholine

cGMP

sGC

GTP

NO

L-citrulline
nNOS

L-arginine

glutamate

CaM

Ca2+

Figure 1.2. Mechanism of production of NO at a neuronal synapse through nNOS. The
production is first stimulated by the release of glutamate to cause the upregulation of
calcium within the connecting neuron. This then leads the conversion of L-arginine to
L-citrulline and NO facilitated by nNOS. NO then leads to the production of cGMP
which regulates ion mediation in neurons along with controlling the presynaptic release
of certain neurotransmitters like acetylcholine.
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Bacterial killing

NO
+ L-citrulline
IFNγ
LPS

iNOS
L-arginine

Figure 1.3. Inducible production of NO through the regulation of iNOS within
macrophages. The only NO pathway that is not calcium-calmodulin regulated. It is
triggered by the interaction of macrophages with specific cytokines (IFNγ) and bacterial
products (LPS). After NO is produced, its main role in this instance is the intracellular
killing of pathogen through the formation of ONOO-.

1.2 Biological Response to Implanted Biomaterials
1.2.1 Response to blood contacting foreign materials
There is huge potential to improve patient interventions by controlling the biological
response toward blood and tissue contacting devices and the materials in which they are
fabricated. The response from the body when a foreign material is introduced to the
biological environment often times causes failure of the implanted device. In the case of
intravascular implants such as sensors and catheters, proteins immediately adsorb to the
surface of the material upon implantation, which platelets then bind to and become
activated (Figure 1.4). Once activated, soluble fibrinogen is converted to insoluble
5

fibrin, forming a clot19-20. This can cause serious complications for the device that is
implanted inside a patient such as incorrect sensor readings or occluded catheters due to
the interference around the sensor area or the lumen of the catheter. Clot formation also
creates a risk for embolism as it can break off of the device and block a vessel further
down the bloodstream.
Device before implantation

Protein adsorption to surface

Platelet adhesion

Fibrin and thrombus clotting

Fibrin

Red blood
cell

Figure 1.4. Biological response to implanted blood contacting biomaterials. Once a
foreign material comes in contact with blood, proteins will immediately adhere to the
surface. This creates binding sites for circulating platelets to attach to and become
activated. After platelet activation, fibrin is formed which leads to even more platelet
adhesion to the surface and eventually a thrombus is formed.
1.2.2 Response to tissue contacting foreign materials
Medical devices that are implanted within the tissue of a patient will undergo a wound
healing response. The inflammatory response is an important part of the wound healing
process in the body, and work together to contain/isolate or remove foreign materials
while remodeling and repairing any tissue damage that occurred around the device. This
response can have negative effects on device functions. One common issue that leads to
their failure is the formation of a fibrous capsule around the implant along with chronic
inflammation occurring due to the constant recruitment of macrophages to the area21. If
a material that is unable to be properly phagocytized by the converging macrophages, it
is completely isolated from the rest of the body with a thick collagenous capsule. Over
time, this can cause a complete loss of functionality of the implant, requiring it to be
6

replaced which subjects the patient to more invasive surgeries. This response is due to
the macrophages present around the implant area attempting to remodel the damaged
extracellular matrix (ECM). During this remodeling phase, an overexpression of
fibronectin by macrophages is present along with the release of pro-fibrogenic
cytokines to increase fibroblast activation22-23. Macrophages release matrix
metalloproteases (MMPs) to facilitate the remodeling, which influence how other cells
migrate to the foreign material and differentiate24.
The evaluation of the biocompatibility of a material is often gauged through histological
analysis over a period of time. The inflammatory response is a complex series of
signaling chemicals and cells that vary in quantity and type (Figure 1.5). Neutrophils
and other emigrating white cells are predominant during the acute inflammation stage
and only last for a few hours to days, but macrophages have also been shown be in their
highest concentration while neutrophils are still present25. This migration of leukocytes
to the injury site is facilitated through the chemotaxis process. A large variety of
chemotactic species are released from the body and attach to receptors on the leukocyte
cell membranes which causes them to permeate through the vasculature to the wound
site and become activated. Once activated, neutrophils begin to phagocytize any foreign
materials by attaching itself to it, engulfing it, and eventually degrading or killing it26. If
the initial cause of inflammation is not resolved during the acute phase, chronic
inflammation begins. This is stimulated from a constant release of pro-inflammatory
stimuli that occur during the acute inflammatory phase. During the chronic
inflammation phase, the presence of neutrophils drastically decreases, and
macrophages, monocytes, and lymphocyte occurrence increases27. There is no longer a
systemic response as the foreign body response is limited to the injury site or
biomaterial.

7

Figure 1.5. Escalation of the inflammatory response and wound healing to an implanted
biomaterial. Time and intensity vary on the chemical and physical properties of
implanted biomaterial and the degree of trauma caused during implantation. Neutrophils
and blood monocytes first migrate to the injury site, then within hours, the blood
monocytes are converted into macrophages. Once chronic inflammation occurs,
neutrophils are removed by the macrophages present and eventually form FBGCs to
remove large particulates. The final resolution is to isolate off the material through a
fibrous capsule. Modified figure previously done by Anderson26.
1.2.3 Macrophage signaling
Macrophage migration and adhesion to foreign biomaterials is the inevitable host
response that causes the most complications for biological implants. For blood
contacting materials, platelets will release a number of chemoattractants like interleukin
(IL-1), transforming growth factor (TGF-β), and platelet-derived growth factor (PDGF)
to allow macrophages to reach the implantation site28. Once macrophages arrive, more
chemoattractants such as PDGF, tumor necrosis factor (TNF-α), and IL-6 are released
from the macrophages themselves to recruit even more to the site28. Implants that are
left in long enough will eventually lead to the formation of foreign body giant cells
(FBGCs). Macrophages that are adhered to the biomaterial surface are signaled by IL-4
and IL-13 to initiate the fusion into FBGCs if the material is too large to be
phagocytized29-31. Surface modifications of implanted polyurethanes have been shown
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to alter the way macrophages adhere and fuse to form FBGCs by introducing silicone
into the polymer matrix showing the possibility to control chronic inflammation on a
material32. However, once FBGCs are formed, the process of frustrated phagocytosis
begins. This process occurs as an attempt to degrade and destroy the foreign substance
that was unable to be removed simply by macrophages. FBGCs will release ROSs,
degradative enzymes, and acid hydrolases at the material surface in an attempt to
remove it33-34. The introduction of ROSs to the environment allows for alterations in
surface chemistry of the implanted material, leading to an even greater loss of material
functionality.
1.2.4 Macrophage phenotyping
Macrophage phenotype also plays a large role in the inflammatory response to
biomaterials and are labeled as either classically activated macrophages, or M1
macrophages, and alternatively activated macrophages, or M2 macrophages. M1
macrophages are activated from the presence of bacterial lipopolysaccharides and
signaling chemicals related with infection35. This phenotype is strongly associated with
the aggressive removal of foreign substances through inflammation and are responsible
for the release of pro-inflammatory cytokines like IL-1β, IL-6, IL-12, and TNF-α36. M2
macrophages are more involved with tissue repair and dealing with parasitic types of
infections37. Instead of increasing the amount of inflammatory cells to be recruited to a
site, this phenotype releases anti-inflammatory cytokines such as TGF-β and IL-10 to
help control it36. The two phenotypes also have very different metabolic pathways of Larginine as well. As described with the NOS enzyme reactions, L-arginine is an
important precursor for the production of NO. The production and utilization of NO
through iNOS is mainly done through M1 macrophages as a means to initiate
intracellular killing to foreign bacteria. M2 macrophages upregulate arginase to
synthesize urea and ornithine which are important for the production of collagen and
cell proliferation38-39. These mechanisms make sense when applied to a typical wound
healing situation, where M1 macrophages are dominant for the first few days to remove
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foreign substances and then M2 macrophages take over after to remodel and repair the
damaged tissue40-41.

1.3 Polymers Used in Biomedical Settings
1.3.1 Parameters for designing polymeric biomaterials
Polymers are one of the most widely used materials in medicine. Their applications are
limitless due to their highly modifiable mechanical and chemical properties which allow
them to be designed for specific situations. Depending on the application a polymer is
needed, there are certain criteria that must be met to ensure the best results42. Implanted
polymers could be required to be a facilitator of mass transfer from a device to the
surrounding tissue. This brings up the issue of porosity of a polymer into question. If
the polymer is transporting large molecules like proteins, it must have a tailored
permeability to allow that transfer. Other types of polymers only need to facilitate small
gaseous molecules like oxygen, and have more lenient porosity parameters. Some
common biocompatible polymers used for limited molecular permeability of water and
other larger molecules are silicone rubbers and polytetrafluoroethylene (PTFE)43-44.
Reactivity is another important parameter that must be taken into consideration for an
implanted polymer. When in contact with tissue, the cells involved in the foreign body
response will release harsh reactive chemicals in an attempt to degrade it. The surface
of a biomaterial will become acidic as a result of this response, sometimes reaching a
pH as low as 445. A polymer must be able to resist this reactive environment as the
inflammatory response progresses. In the late 1980’s, polyether polyurethane
elastomers were used for pacemaker lead insulation over silicone rubber due to their
better mechanical and chemical properties. Over time, device failure occurred due to
environmental stress cracking within the polymer. This occurred due to chemical ion
oxidation that led to the cleavage of the polymer chains, causing a reduction in
mechanical properties20. Chemical modifications are a popular method to make
polymers relatively inert in the body to prevent this type of complication. Some
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polymers have reactive functional groups allowing for the attachment of drugs or
proteins to increase the biocompatibility and lower the reactivity to local chemical
species.
1.3.2 Biodegradable polymers
If the implanted material is only temporary but requires reintegration and remodeling, a
degradable material with nontoxic byproducts is often a good choice for materials
selection. One of the most popular clinically used polymers for this type of application
is poly-L-lactic acid (PLLA). PLLA is a biodegradable, crystalline polymer with
excellent mechanical properties for applications such as sutures. The properties of the
PLLA can be tuned such that it can take as long as 2 to 6 years before it is completely
reabsorbed into the body, which is much longer than most biodegradable polymers used
in medicine46-47. Other biodegradable polymers have faster degradation times such as
polyglycolide (PGA), which has been used as a copolymer with PLLA to form
poly(lactide-co-glycolide) (PLGA), which has adjustable degradation times based on
the ratio of PGA to PLLA48.
1.3.3 Hydrogels
Hydrogels are another class of polymer with many uses in medicine. They are described
as synthetic, hydrophilic polymers that swell when exposed to water49. This property
allows hydrogels to be applied to areas of controlled drug release. As water enters the
polymer matrix, polymeric chains become more loosely bound, allowing the release of
any drug the hydrogel could be containing50. Hydrogels most commonly release their
desired drugs from a physical change (pH, temperature, hydrophobicity) rather than
through a typical chemical reaction where covalent bonds are cleaved. Along with drug
release, the structural aspect of hydrogels is also an important parameter. Polyethylene
glycol (PEG) hydrogels specifically have been used as tissue repair scaffolds. PEG has
the ability to change its material properties simply by adjusting parameters such as
crosslinking density and molecular weight to alter the material and chemical properties
11

of the hydrogel51. Chemical crosslinking needs to be taken carefully into consideration
as some crosslinkers can react with the drug trying to be administered, causing the
formation of unwanted, possibly toxic products, which will eventually lead to a large
immune response from the host52.
1.3.4 Hydrophobic polymers
Unlike the polymers used in hydrogels, hydrophobic polymers have no water uptake
and have unique properties when in contact with cells and tissue. The most popular
class of hydrophobic polymers used in biomedical applications are silicone rubber
based materials. Polydimethylsiloxane (PDMS) based silicone rubber have been shown
to have excellent biocompatibility, low toxicity, stability in a physiological
environment, and are chemically inactive53-56. Using a hydrophobic material like PDMS
is useful for long lasting implantable applications that resist the cellular infiltration and
remodeling seen in the biodegradable and hydrophilic materials. Like any long term
implanted material, PDMS and other hydrophobic polymers still see issues of chronic
inflammation, showing that another modification to these materials is needed to
overcome the body’s response to foreign materials.

1.4 Background of Current Nitric Oxide Donating Materials
1.4.1 Nitric oxide chemistry
In order to be able to mimic the body’s range of production of NO at different
physiological locations, many NO donating materials have been synthesized. Since NO
is a highly reactive free radical molecule, strategies of covalently linking it to materials
to stabilize and control it were developed. The two most widely used synthetic NO
donors are based on the chemistry of S-nitrosothiols (RSNOs) and N-diazeniumdiolates
(NONOates). Choosing which type of NO donor is important as each has their own set
of release mechanisms, stability under physiological conditions, and covalent linking
chemistry. Having a wide variety of controllable parameters gives a large amount of
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flexibility when deciding where and how you want NO to be delivered. This localized
and highly controlled delivery is important to harness the therapeutic potential of NO in
part because NO has a half-life ranging from seconds to minutes depending on the
physiological environment it’s exposed to57-59.
1.4.2 S-Nitrosothiols
For RSNO modified materials, there is a degree of control with how NO is administered
to an area as can be highly stable under in vivo conditions if appropriate precautions are
taken. The main mechanisms for NO to be cleaved from an RSNO system are by light
and metal ions60-61. Photolytic cleavage of the sulfur-nitrogen bond occurs at the
wavelengths of 340 nm and 545 nm62. Knowing this chemical property gives the
possibility of using RSNO based materials as a controlled therapeutic for the
administration of NO. RSNO’s are among the safest and most biocompatible NO
donors to use within materials as they are produced endogenously in the form Snitrosoglutathione (GSNO). This formation occurs by the reaction of glutathione (GSH)
with N2O3 to form GSNO. A key RSNO that is used for NO delivery from polymeric
biomaterials is S-nitroso-N-acetyl-D-penicillamine (SNAP) (Figure 1.6). Both SNAP
and GSNO have been shown to have positive effects to vasculature in respects with
vasodilation and preventing platelet adhesion63. SNAP is more reactive with ions such
as iron and copper to trigger NO release than GSNO. The reaction of copper with
RSNOs has been thoroughly investigated as one of the key metal triggers. Copper (II)
ions (Cu2+) specifically interact with RSNOs by first being reduced to Cu+ by thiol
anions present. Cu+ is then able to cleave the sulfur-nitrogen bond while being
regenerated back to Cu2+ The cleaved sulfur complexes can then form disulfide bonds
as the reaction cycle continues64.
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Figure 1.6. Structure of S-nitrosoglutathione (GSNO) and S-nitroso-N-acetyl-Dpenicillamine (SNAP). GSNO is an endogenous S-nitrosothiol commonly found in the
body while SNAP is used in chemical synthesis to artificially add nitric oxide donating
groups to synthetic materials.
1.4.3 N-diazeniumdiolates
Diazeniumdiolates, also known as NONOates, are a class of zwitterionic compound that
are used in the NO donating research field with different chemical properties compared
to RSNO’s. The first investigation of using NONOates as a potential drug administering
molecule was done by Dr. Larry K. Keefer at the National Cancer Institute. The release
kinetics and dissociation properties of NONOates were investigated and proved to have
useful characteristics under physiological pH and temperature65. Two molecules of NO
per NONOate molecule are able to be produced and these NONOates can have a halflife of up to 20 hours under these conditions, depending on the surrounding functional
groups66. The release mechanism of NO from these molecules is either via proton
mediated decomposition or thermal degradation66. This opens up a wide range of
applications for areas that require short and large high amounts of localized NO as the
donor can be covalently bound to larger molecules or polymers. However, these
molecules some of the controllability and in vivo longevity compared to some RSNOs.
Dimethylhexanediamine diazeniumdiolates (DMHD/N2O2) is a popular NO donating
material for these applications, and has been blended in with multiple polymer matrices
to demonstrate its ability to release a large amount of NO over a short duration (Figure
1.7).
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Figure 1.7. Structure of dimethylhexanediamine diazeniumdiolates (DMHD/N2O2).
This zwitterionic NO donating structure allows for the release of two moles of NO per
molecule when placed under physiological conditions. The release is passive and very
rapid – making it an excellent choice of NO donor for short term passive release.

1.5 Applications of Nitric Oxide Donating Materials
1.5.1. Concerns for nitric oxide concentration
Determining the proper amount of NO to be administered to an area in the body when
developing synthetic NO releasing materials is critical. Depending on the level and
duration of NO generated, it can be used to mediate cell proliferation and protect them,
or it can be used to trigger cell apoptosis. Concentration of NO determines how far NO
is capable of diffusing and consequently what type of signaling molecules it interacts
with. Table 1.1 gives an overview of the range of concentrations NO and its
corresponding cellular function. Although the concentrations are given in molar
concentrations, in a true physiological environment, NO exists mainly as a flux being
emitted from a cellular source. The concentrations stated are estimates based on the NO
dissolved in solution around the environment.
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Table 1.1. Effect of NO when administered at varying concentrations to certain cell
types.The effects of NO have a large variety based on the concentration being
administered, along with where in the body the release is occurring. When developing
synthetic materials that are able to release NO, it is important to be aware of the
concentrations being administered to achieve the desired outcome.

NO

Physiological Effect

References

concentration
1-30 nM

•

Endothelial cell release of NO (eNOS

67

mechanism)
•

Leads to smooth muscle relaxation
through conversion of sGC to cGMP

30-60 nM

~100 nM

•

Maintains vascular tone

•

Cell proliferative effects

•

Levels emitted from tumor cells

•

Tumor proliferation

•

Antiapoptotic

•

Hypoxic inducible factor 1α (HIF-1α)

68-69

69-70

accumulation

~400 nM

•

VEGF accumulation

•

Upregulation of p53 – caused by damage
to DNA

•

Antipathogen and tumorcidal

•

Macrophage release of NO (iNOS
mechanism)
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70

>1 µM

•

Nitrosative stress - Protein

71

nitrosation/nitration
•

Inhibition of DNA repair and
mitochondrial respiration

•

Leads to full cell cycle arrest

1.5.2 Improving biocompatibility of foreign devices
Controlled NO releasing materials that are capable of delivering the appropriate level of
NO at the appropriate time can be used to improve biocompatibility of blood and tissue
contacting devices, creating safer and more effective implanted devices such as
intravascular and subcutaneous sensors, and has the broader potential to improve
performance of virtually all implanted biomedical devices. A specific example would be
synthesizing a material to copy the NO release seen from healthy vasculature, which is
estimated to be approximately 0.5-4 x 10-10 mol cm-2 min-1 depending on the specific
location within the circulatory system72. Various polymeric materials have been
fabricated that release NO at this level and have shown much success in inhibiting
platelet adhesion and activation to foreign blood contacting materials and lowering the
chronic inflammatory response of subcutaneous tissue contacting materials73-77.
Experimental setups have been design using an extracorporeal circuit (ECC) for in vivo
experiments on rabbits to prove NO releasing material’s effect on platelet adhesion to
foreign materials78.
1.5.3 Interaction with macrophages and mast cells
NO’s effect on macrophages is still being investigated as various levels of NO can
influence them in different manners. When trying to apply an NO donating material to
ward off macrophage attachment and recruitment, NO flux must be carefully
considered. Large amounts of NO being delivered to a site where macrophages are
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present can prevent the production of recruitment cytokines, while small amounts can
actually influence a higher production of these inflammatory inducing cytokines79.
Lung macrophages in culture have been treated with NO from SNAP at concentrations
ranging from millimolar to micromolar, and were shown to have a decrease in proinflammatory cytokines80. There is also the risk of trying to utilize a high, uncontrolled
dose of NO to prevent this signaling as a bolus of NO will cause cell death and tissue
necrosis.
Mast cells are another large contributor to the immediate inflammatory response to a
biomaterial. The primary function of mast cells is the release of histamine to cause
vasopermeation between vascular endothelial cells to allow the migration of leukocytes
to the injury site. NO has been previously shown to inhibit the histamine release from
activated mast cells to mediate this inflammatory response81-82. Specifically, NO’s
interaction with interferon gamma (IFN-γ) was investigated. IFN-γ induces NO
production from nearby cell populations, which then directly inhibits mast cell
degranulation83-84. Experiments were performed by inhibiting NO production through
NOS by administering a competitive inhibitor in a culture of tissue type mast cells
containing IFN-γ. Once the NO production was allowed, there was a drastic decrease in
serotonin release from mast cells, signifying NO’s effect to prevent degranulation.
Degranulated mast cells also release cytokines like IL-4 and IL-13, which play large
roles in determining how harsh and long the foreign body reaction will persist85. Using
NO to prevent this degranulation process and release of cytokines could be a large
benefit for slowing chronic inflammation.
1.5.4 Role in vascular diseases
Applying NO release as a treatment for vascular disorders has also been studied. After
balloon angioplasty treatment, there is damage to the endothelium which eventually
leads to myointimal hyperplasia caused from the migration of smooth muscle cells to
the lumen of the vasculature and eventually proliferation86. A cascade of events then
occur which causes the occlusion to worsen – smooth muscle cells change phenotype
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and start to produce ECM, the adhesion of platelets to the newly formed ECM, and
eventually the recruitment of more inflammatory cells to the region worsen87. NO at
these damaged vascular sites can prevent all of these negative effects caused as vascular
smooth muscle cell proliferation is inhibited by NO as well as platelet activation as
mentioned previously88. Other disorders that are due to a reduction in NO activity
within vasculature are hypercholesterolemia and atherosclerosis89-90. Oxidized lowdensity lipoproteins (LDLs) are the leading cause for hypercholesterolemia as it reacts
and inactivates endogenous NO91-92. It also causes the generation of superoxide anions
from the endothelium and migrating macrophages, creating an environment of high
oxidative stress41. This highly oxidative area scours and reacts with NO that would
otherwise be promoting healthy vascular function. For coronary artery diseases,
saphenous vein grafts eventually undergo atherosclerosis and vessel occlusion within
the first 10 years due to the migration and proliferation of smooth muscles cells93.
nNOS gene transfer to these saphenous vein graft sites demonstrated the ability of NO
to a large reduction in these negative effects, prolonging the life of these grafts94.
1.5.5 Cancer therapeutic applications
Another application for highly controlled NO releasing materials is in drug delivery to
tumors. NO in appropriate doses is known to induce apoptosis in cells and could
function as an effective local cancer treatment95. NO in an oxidative environment reacts
to create peroxynitrites, which is seen specifically in activated macrophages. Tumors
have been shown to have increased levels of superoxides and other ROSs, giving NO
the ability to be a potent cancer therapeutic when applied correctly96-69. If exposed to
the right level of NO, the cancerous region would be exposed to localized oxidative
byproducts, damaging the tumor, while other nearby areas could be left relatively
unharmed as the ROS level would be much lower. This level of NO must be
administered carefully as certain fluxes of NO can also increase tumor angiogenesis97.
NO has been shown to promote vascularity and increase the production of vascular
endothelial growth factor (VEGF) in endothelial cells98.
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1.5.6 Reendothelialization of vessels
In other environments, the increase in vascularity from endothelial cells could be seen
as a positive effect. Decellularized vascular implants or biodegradable materials that
need cellular infiltration and revascularization would benefit greatly from the increase
in production of VEGF from endothelial cells, allowing the opportunity of NO donating
materials being able to revascularize vessel grafts at a much quicker rate while still
preventing unwanted inflammation at the implantation site74, 98-99. In unmodified vessel
grafts, smooth muscle cells are the primary cell type that infiltrate and proliferate,
causing occlusion of the vessel. NO would be able to promote the infiltration of
endothelial cells in its place from the neighboring endothelial cells. Grafts incorporating
NO have been done previously and shown to prevent platelet adhesion and recruitment
to these sites that would otherwise perpetuate this inflammatory response to eventually
lead to graft failure100.

1.6 Detection Methods of Nitric Oxide
1.6.1 Griess assay
The most important part of analyzing any NO releasing material is the methods used to
determine and quantify the release into the surrounding environment. Since NO is a free
radical gas, accurate detection becomes complex due to its high reactivity with the
surrounding environment. A popular method to determine NO production is to measure
the amount of nitrites in solution is through the Griess assay, which was formulated by
Peter Griess in 1879101 (Figure 1.8). This method can be used to quantify the amount of
NO in solution by indirectly measuring the oxidation products that are formed when
reacted with oxygen. These oxidation products can then react with sulfanilamide and N1-naphthylethylenediamine to form a fluorescent azo dye. Using a plate reader, the dye
formed can be detected using a 550 nm filter which then quantifies the amount of NO
being converted to nitrites. The absorbance found can then be compared to a calibration
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curve of nitrite values to give the amount of NO released into solution. This method can
give false results though as NO can readily react with oxygen in solution to form nitrate
molecules, which would give lower amounts of NO than what is being measured102.
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Figure 1.8. Chemical detection of NO through the Griess reaction.
NO is first converted into a nitrite product, where it then interacts with sulfanilamide
and N-1-napthylethylenediamine to form a fluorescent detectable dye which is
detectable at 540 nm. This can then be used to quantify the amount of NO that was
released within a solution.
1.6.2 Electrochemical
Electrochemical detection of NO is another method for quantifying NO release from a
material (Figure 1.9). There are two strategies for electrochemically identifying NO –
electrooxidation and electroreduction through the use of Ag/AgCl electrodes.
Electrooxidation reduces NO to generate N2O22- through a single step, two electron
reaction, while electroreduction of NO is completed through a three step pathway where
NO is oxidized to form nitric acid, and then is further oxidized in water to form NO3103-104

. Electrochemical electrodes have been shown to be able to detect NO
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continuously in a biological environment that is generating NO in real time105. This
would give insight to NO generation from cells in vivo as electrodes can be constructed
small enough to monitor vasculature and organs. The downside for this method is that
its detection limit of 1 µM is much less sensitive when compared to the
chemiluminescent and Griess assays106. There could also be interference based on how
far the electrode is from the site that is generating NO. In an in vivo environment, NO
has a very short half-life and might not even come into contact with the electrode if it is
not placed properly107.
Electrooxidation
2NO + 2e

-

N2O22-

Electroreduction
NO+
NO - e
NO+ + OH

-

HNO2

-

H+ + NO2

Figure 1.9. Chemical mechanisms for the electrochemical detection of NO. Through
electrooxidation, NO undergoes a two electron reduction to form N2O22-.
Electroreduction goes through a multistep oxidation path to form NO2- from NO.
Concentration of NO is then measured by referring the current recorded to a known
calibration standard.

1.6.3 Chemiluminescence
The most accurate method to directly measure NO coming from a either a NO releasing
sample or cells in media is through chemiluminescence (Figure 1.10). Using a system
purged with nitrogen, there are no reactive side products to interfere with NO
measurement as seen with other NO detection assays. It also gives a detailed profile of
NO being released over a period of time. This allows the calculation of NO fluxes from
cells and materials, which is an important parameter to keep in mind when calibrating
NO releasing biomaterials to the physiological levels of release seen in the body. For
this detection method, NO reacts with ozone to produce oxygen and nitrogen dioxide in
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an excited state. During the relaxation of nitrogen dioxide, a photon is emitted which
can be measured108.
*
NO2 + O2

NO + O3
*

NO2 + hv

NO2

Figure 1.10. Mechanism for the detection of NO through chemiluminescence. NO is
initially reacted with ozone to form a nitrogen dioxide in the excited state. As this
molecule relaxes, it emits a photon which can then be measured and quantified.

1.7 Statement of Purpose
Knowing all of the beneficial effects and applications of NO is crucial when developing
a unique NO donating material. Chapter 2 describes an NO donating PVC material
which utilizes covalent bound RSNOs. By covalently attaching the NO donor to the
backbone of the polymer, it allows a uniform NO flux across the polymer area when
triggered by light for controlled release. This characteristic gives it beneficial uses for in
vitro NO delivery models. Chapter 3 utilizes dendrimer chemistry to develop a highly
branched polymeric structure capable of high NO storage. Most NO donors that
passively or actively release NO do not last for long periods of time. By synthesizing a
hyperbranched molecule with high NO capacity, a polymer can be loaded with a
tremendous amount of NO capable of delivering NO longer than most other NO donors.
Chapter 4 describes how subcutaneous inflammation can be controlled using the two
materials previously described. The foreign body response to subcutaneously implanted
devices dramatically reduces its longevity. By utilizing these beneficial effects of NO
described, the developed materials were used to prevent the harsh inflammatory
responses normally observed. This can then be applied to any future subcutaneously
implanted devices to increase its implantation life, reducing the amount of interventions
required to constantly replace sensors needed to record specific analytes. The
preliminary data in chapter 5 delves into the potential effects NO can have on viruses.
The mechanisms by which macrophages use NO to kill foreign bacteria is hypothesized
23

to destroy viruses in a similar manner, but the exact dosage is still unknown. The
groundwork for that chapter describes an accurate method of delivering NO to viruses
suspended in solution to find this dosage level.
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Chapter 2 : Controlled Nitric Oxide Release from
Covalently Linked S-Nitroso-N-Acetyl-D-Penicillamine
to Polyvinyl Chloride (SNAP-PVC)
2.1 Introduction
PVC is the most widely used polymeric material used in medical applications ranging
from blood bags, heart lung bypass sets, endotracheal tubes, and many other medical
related materials1. Around 25% of all biomedical devices contain some form of PVC
due to its wide range of mechanical property variability with plasticizer additives2.
Some of the plasticizers that can be used in PVC are toxic such as di-(2-ethylhexyl
phthalate) (DEHP), and are able to leech out of the polymer into the blood3,4. Although
these ester based plasticizers are toxic, much safer PVC plasticizers have been
developed to be used for blood contacting purposes. Examples of non-toxic plasticizers
that are blendable with PVC are citrates and sebacates1,5. Plasticizer leeching can also
be controlled by performing surface modifications to the polymer. A common technique
used is surface crosslinking, which acts as a barrier to prevent the escape of any
unwanted chemicals6. This can also be useful for an NO releasing blendable compound
that is designed to only release NO at a certain area and time and not diffuse out of the
material. PVC is also has a very low cost to manufacture compared to other medical
grade polymers and has a strong resistance to external chemical components. Being able
to chemically modify a polymer is also an important characteristic of a polymer. The
free chlorine reactive groups allow for the attachment of other chemical components to
further enhance the surface chemistry of PVC. Chemically modifying the plasticizers
used within the polymer is also an option for attaching small molecules which is a
popular strategy for NO releasing polydimethylsiloxane (PDMS), a well characterized
NO donating material7,8. 1

1

Material in this chapter is in the process of being submitted for publication.
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Polymers can be synthesized to mimic the endothelium’s NO release levels to prevent
unwanted foreign body response. A novel NO releasing PVC based polymer is
described and shown to have tunable NO releasing properties depending on the trigger
mechanism. NO releasing PVC has been reported by blending N-diazeniumdiolates
within the polymer matrix and covalently binding it to a modified version of the
polymer9,10. N-diazeniumdiolates do not have the controllability that RSNOs contain as
they are limited to only passively release their NO reservoir over a short time11. Using a
SNAP based system, a material is able to have a tunable control of NO release for a
variety of situations along with the possibility to create a passive release system.
When developing an NO releasing polymer, the capability of NO diffusion through a
polymer matrix is important. NO permeability through PVC has been characterized
using Fick’s law of diffusion where the equation is as follows:

ln �
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Where C is the concentration of NO, D is the diffusion coefficient, A is the area being
diffused through, l is the path length, V is the chamber volume, and t is the time.
Although its diffusion kinetics are not as good as silicone rubber, it is greatly enhanced
through the addition of the plasticizer dioctyl sebacate12. This needs to be taken into
consideration when a system with mass transfer of NO through PVC or any other
polymer is designed. NO releasing materials that are blended within a polymer matrix
while in contact with blood will need to be designed with a layer that prevents diffusion
of the NO donor out of the material, but still allows the permeability of NO itself. This
diffusion rate can be tailored to the dosage of passive NO being administered as well.
Having an additional parameter available to modulate the rate of NO release could be
beneficial.
Herein, a synthetic route is described where (PVC) is aminated to a specified extent and
then further modified by covalently linking S-nitroso-N-acetyl-D-penicillamine (SNAP)
groups to the free primary amine sites to form a nitric oxide releasing polymer (SNAP37

PVC). Controllable release of NO from SNAP-PVC is described using photoinitiation
from light emitting diodes (LEDs). Ion mediated NO release is also demonstrated as
another pathway to give a passive mechanism for NO delivery. The large range of NO
fluxes obtainable from the SNAP-PVC films demonstrates the potential uses in
mediating unwanted inflammatory response in blood and tissue contacting devices.

2.2 Experimental Details
2.2.1 Materials
Polyvinyl chloride (average Mw = 233,000, Mn = 99,000), ethylenediamine, 5, 5’dithiobis (2-nitrobenzoic acid), triethylamine, 1,4,8,11-tetraazacyclotetradecane, Nacetyl-D-penicillamine (Fluka), and concentrated hydrochloric acid were obtained from
Sigma-Aldrich (St. Louis, MO, USA). ATTO-TAGTM FQ reagent was purchased from
Invitrogen (Grand Island, NY, USA). Tert-butyl nitrite (90% technical grade, Acros
Organics) was purchased from Fisher Scientific. Magnesium sulfate, copper (II)
bromide, L-ascorbic acid sodium salt, and acetic anhydride (Alfa Aesar) were
purchased from VWR (West Chester, PA, USA).
2.2.2 Synthesis of NAP-thiolactone
The procedure to synthesize a self-protected N-acetyl-D-penicillamine (NAP)
thiolactone was accomplished according to the procedure from Moynihan and Robert13
(Figure 2.1). 5g of N-acetyl-D-penicillamine was dissolved in 10 mL of pyridine while
10 mL of acetic anhydride and 10 mL of pyridine were mixed in a separate container.
The solutions were both cooled in an ice bath for 1 h before being combined. The
mixture was allowed to stir at room temperature for approximately 24 h until the
solution turned light red. The solution was rotary evaporated at 45˚C until the solution
stopped boiling. The temperature was then increased to 60˚C until most of the solvent
was evaporated to obtain an orange viscous liquid. The resulting product was then
dissolved in 20 mL of chloroform and washed and extracted three times with 20 mL of
38

1M HCl. MgSO4 was added to the chloroform solution to remove any water and was
then removed by vacuum filtration. The chloroform was removed by rotary evaporation
at room temperature and the resultant crystals were collected and rinsed with hexanes
and filtered. Light yellow/white colored crystals were recovered and vacuum dried
overnight.

O

SH

O

S

O
HO
NH2

Acetic Anhydride
Pyridine
18-24 hr

NH

N-acetylpenicillamine thiolactone

N-acetyl-DL-penicillamine

Figure 2.1. Synthesis of thiolactone self-protected N-acetyl-D-penicillamine (NAPthiolactone). The base molecule N-acetyl-D-penicillamine is first dissolved into chilled
pyridine and acetic anhydride where it is then allowed to stir for approximately 24
hours. The pyridine is then rotary evaporated off and the resulting viscous liquid is
dissolved in chloroform and extracted three times with 1M HCl. Any excess water is
removed by placing anhydrous magnesium sulfate into the organic solution and filtered
off. The chloroform is then rotary evaporated off at room temperature and rinsed with
hexanes to give a white/light yellow crystalline product.
2.2.3 Synthesis of SNAP-PVC
The overall schematic to synthesize SNAP-PVC is shown below in Figure 2.2.
Aminated PVC was first synthesized using a modified procedure from Tinkilic et al14.
2.5 g of PVC was suspended in 50 mL of methanol, 11 mL of triethylamine, and heated
to 60˚C. 15.25 mL of ethylenediamine was added once the solution reached
temperature. The reaction mixture was allowed to reflux for at varied time points (1, 2,
and 4 hours) at 60˚C. The resulting light yellow polymer powder was then filtered and
washed thoroughly with water, methanol, 1M HCl, methanol, and water in that order
before being dried under vacuum.
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200 mg of the synthesized PVC-NH2 was dissolved in 10 mL of anhydrous N, Ndimethylacetamide (DMAC). 60 mg of NAP-thiolactone was then added to the mixture
and allowed to stir overnight. 2 mL of the NAP-PVC solution was taken out and
nitrosated using 0.5 mL of t-butyl nitrite. The t-butyl nitrite was first chelated of any
copper stabilizer using a 30 mM aqueous cyclam solution (1, 4, 8, 11tetraazacyclotetradecane). For the chelation step, approximately 3 mL of t-butyl nitrite
and 5 mL of 30 mM cyclam were mixed and stirred vigorously. The cyclam was then
removed and the t-butyl nitrite was rewashed with more cyclam a total of three times
before the cleaned t-butyl nitrite was extracted and stored at 2oC. The light yellow/clear
solution of PVC-thiolactone turns a light green-yellow color after allowing it to react
with t-butyl nitrite for 24 hours. The SNAP-PVC solution was then cast into
polytetrafluoroethylene (PTFE) rings and left to air dry overnight to form a thin layered
polymer film. The films can also be dried under a vacuum as moisture will cause the
films to be less transparent, hindering the ability the LED can trigger photoinitiated NO
release.
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Figure 2.2. Synthesis route of SNAP-PVC. PVC is first modified to contain reactive
primary amine site by suspending PVC resin in methanol, triethylamine, and
ethylenediamine while refluxing at 60oC. This attaches the ethylenediamine to the PVC
backbone. The free primary amine can then react with NAP-thiolactone to form a NAPPVC polymer. Nitrosation of the free thiol group was then done through the reaction of
t-butyl nitrite to form SNAP-PVC.

2.2.4 Polymer characterization
The quantification of the degree of amination of the PVC was done by using the ATTOTAG FQ test for primary amines. Fluorescence testing was done using a 96-well plate
reader (BioTek Instruments) and the amount of primary amines was determined using a
glycine calibration curve. The fluorescent tag is maximally excited at 450 nm with an
emission maximum at 550 nm15. Once the aminated PVC reacts with NAP-thiolactone,
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a free thiol is exposed on the polymer backbone. Ellman’s test for thiols was done to
quantify the amount of thiols grafted onto the polymer using 5, 5’-dithiobis (2nitrobenzoic acid) (DNTB) following a modified protocol developed by George
Ellman18. Tris-buffer was substituted with PBS (pH = 7.4). Absorbance was then taken
at 412 nm after the reaction with 5,5'-dithio-bis-2-nitrobenzoic acid (DTNB) using a 96well plate reader. As the reaction progressed, FTIR was done to characterize the
important polymer functional groups (Mattson Genesis II).
2.2.5 Quantification of primary amines
Primary amines are able to be accurately quantified through their reaction with 3-(2furoyl)quinoline-2-carboxaldehyde (FQ) to form a fluorescent isoindole product17
(Figure 2.3). This is an extremely sensitive method, able to detect amines in the
attomole (10-18) range. The development of this detection method was originally made
to quantify trace amounts of peptides and amino acids that could not be identified
through traditional methods like liquid chromatography and capillary electrophoresis.
The application can be applied to synthetic materials with a primary amine present. The
reaction that occurs with FQ, potassium cyanide (KCN), and the primary amine
containing sample is shown in the schematic below.
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Figure 2.3. Mechanism for the fluorescent detection of primary amines using the
ATTO-TAG FQ amine derivation kit.3-(2-furoyl)quinoline-2-carboxaldehyde (FQ) in
the presence of a potassium cyanide will react with a primary amine site to form a
fluorescent product. This product has an excitation wavelength of 450 nm and an
emission maximum of 550 nm, which can be quantified to give an accurate
measurement of primary amines in a material when compared to a calibration curve.
For a control, glycine-HCl was used and diluted to multiple concentrations to generate a
calibration curve. Each well to be tested on the 64-well fluorescent plate contained
10µL of 10mM CBQCA, 20µL of 10mM KCN, and 10 µL of sample. The reaction was
allowed to sit on a shaker plate for 1 hour while protected from light before being tested
in the plate reader with an excitation wavelength of 450 nm with an emission maximum
at 550 nm.
43

2.2.6 Quantification of thiols
Thiol quantification through the use of DTNB directly cleaves the DTNB molecule into
two TNB anions, where one of the free molecules reacts with the thiol being measured
(Figure 2.4). The other TNB anion is what is measured by the spectrophotometer at 412
nm. Cysteine was used to generate a calibration curve up to an absorbance of 1.0. Any
absorbance above 1.0 would not be measured as Beer’s Law cannot accurately predict
concentrations above those values.
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Figure 2.4. Mechanism for the detection of free thiols using Ellman’s assay. 5,5'-dithiobis-2-nitrobenzoic acid (DTNB) has its disulfide bond cleaved in the presence of free
thiols. The free thiol then forms another disulfide bond with one part of the DTNB
while the measured product is emitted into solution and is quantifiable at 412 nm when
compared to a calibration standard.
2.2.7 Nitric oxide release by photoinitiation
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The light source used for photoinitiation of the SNAP-PVC films were 460 nm blue
VAOL-5GSBY4 LEDs obtained from Mouser Electronics Inc (Mansfield, TX, USA).
A 130 Ω resistor was hooked up in series with the LED and a variable voltage source
was applied to the system. The emission spectra and relative intensity of the LED with
respect to drive current is shown to be linear over the currents being used to power the
LED for the study and was characterized by Starrett et al16.
2.2.8 Nitric oxide measurements
Nitric oxide release from the polymer was directly measured by the chemiluminescent
reaction of NO with ozone using a Sievers 280i Nitric Oxide Analyzer (GE
Instruments). SNAP-PVC films with a diameter of 5.5 mm were placed inside an amber
glass sample holder with an inlet nitrogen sweep gas flowing at 200 mL min-1. The LED
was mounted in the top of the sample holder 5 cm above the film to be tested. Varying
voltage levels were used (0, 3, 4.5, 6, 7.5 volts) at 130 Ω to demonstrate the control of
the nitric oxide flux from the polymer film. Total NO release of the polymer films was
done by cleaving the sulfur-nitroso bond through copper mediated decomposition
following a procedure developed by Frost et al17. A solution of 10 mM CuBr2 and a
100 mM solution of L-ascorbic acid sodium salt were used for the NO quantification. 2
mL of the CuBr2 solution are placed in a glass sample holder containing a weighed
SNAP-PVC film. After 5 minutes, 500 µL of the 100 mM L-ascorbic acid solution is
then added to reduce the Cu2+ ions to Cu+, enhancing the sulfur-nitroso bond cleaving.
The test was continued until all of the NO reservoir was depleted.

2.3 Results and Discussion
2.3.1 FTIR analysis
Each step from the reaction schematic shown in the SNAP-PVC synthesis route is
verified using FTIR which is seen in Figure 2.5. After attaching ethylenediamine to the
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PVC backbone, primary amines and secondary amines are present in the spectrum
which is seen in the N-H bending at 1641 cm-1. The attachment of NAP-thiolactone to
the free primary amine sites shows the formation of NAP-PVC as the presence of a
carbonyl peak is present at 1750 cm-1.

Figure 2.5. FTIR spectrum of PVC (green), PVC-NH2 (blue), and NAP-PVC (red).
Once ethylenediamine is attached to PVC, the presence of N-H bending is seen at 1641
cm-1. The attachment of NAP-thiolactone to the free amine shows the appearance of the
amide carbonyl peak at 1750 cm-1 along with the secondary amine stretching around the
3300 cm-1 region.

2.3.2 Quantification Results
Quantification of the amination of PVC was verified through using the ATTO-TAG FQ
test for amines. Once the NAP-thiolactone ring opens and reacts with the primary amine
sites on the polymer backbone, free thiol groups are exposed. To identify the extent to
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which this reaction is occurring, Ellman’s test for thiols was done. The quantification of
primary amine and thiol functional groups were normalized per milligram of polymer.
Primary amine quantification showed 0.201±0.013 µmol/mg of PVC-NH2. Thiol
quantification showed 0.153±0.009 µmol/mg of NAP-PVC. To verify the capacity,
copper mediated NO release was performed on the nitrosated polymer (SNAP-PVC)
and showed the NO released to be 0.0392 ±0.004 µmol per milligram of polymer,
which is a 25.6% NO addition efficiency of the NAP-PVC compound.
2.3.3 Nitric oxide release results
The physiological NO flux for healthy vasculature is estimated to be in the range of 0.5
– 4 x 10-10 mol cm-2 min-1, which is achieved from the SNAP-PVC films at certain
intensities of light. The NO flux varies depending on the location in the body.
Vasculature with higher sheer stress will promote more NO release from vascular
endothelial cells19. After damaging the vascular walls from an implanted device, more
NO release may be initially required to prevent unwanted immune response and
neointimal hyperplasia in the affected area20. Developing a material that is able to adjust
the NO flux in real-time increases the number of applications a hydrophobic polymer
coating could have in a medical setting.
The NO release profile from SNAP-PVC films (diameter 5.5 mm, thickness 0.1 mm) at
varying drive current applied to a 470 nm wavelength LED is shown in Figure 2.6.
Nitrogen sweep gas carried the NO released by photoinitiation to the NOA to give a
stair step profile based on the voltage supplied to the LED. The profile shows the wide
range of control that the polymer is able to obtain. As the LED is adjusted, there is little
decay in the NO being released at each level showing the stability of the NO reservoir
within the polymer.
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Figure 2.6. Controlled NO release profile of SNAP-PVC at varying LED voltages. A
baseline is first obtained with the LED off, and is then turned on with a 3V supply at
130Ω. It is then turned off again until the baseline is reached again before being
supplied with an additional 1.5V while holding the resistance constant. Once 7.5V is
reached, the processed is repeated but with a decreasing supply of 1.5V.
NO release of SNAP-PVC in phosphate buffered saline (PBS) at 37oC was also tested to
show the release under physiological conditions. Ions are able to penetrate the polymer
film and interact with the reactive SNAP groups as PVC is a popular polymer used in
ion selective electrodes21. This provides another pathway to stimulate the NO response
for in vivo applications as other methods like photoinitiation could cause complications
when implemented. In some scenarios, having a level of passive release over a short
period of time may be the desired route of NO delivery. This follows a similar release
profile as seen with N-diazeniumdiolate NO donors, but is able to release lower
amounts over a longer period of time. The passive release of SNAP-PVC in PBS at
37oC is shown in Figure 2.7.
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Figure 2.7. NO release profile of SNAP-PVC placed in PBS at 37oC. 5.5 mm diameter,
100 µm thick films were submerged in 2 mL of PBS while stirring at physiological
temperature to demonstrate SNAP-PVC’s passive NO release. This profile is similar to
NONOates but is able to persist a lower and more constant release.

The NO capacity and release demonstrated by SNAP-PVC could potentially be much
larger as there are many unreacted chlorine sites on the backbone of the polymer. A
longer reaction time with ethylenediamine could be implemented to achieve a higher
degree of amination, but complications with crosslinking and solubility occur as PVC
becomes more dechlorinated22. This limits the amount of NO storage capacity of PVC
through using a component like ethylenediamine as an aminating agent. PVC also
becomes darker in color the more dechlorinated it becomes, which would hinder the NO
release by photoinitiation as light penetration through the film will be limited. NO
release from films reacting with ethylenediamine from 1 to 4 hours was tested, and 2
hours was found to have the highest capacity and release ability of NO, which is
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demonstrated in Figure 2.8.

Figure 2.8. SNAP-PVC photoinitiated NO release at 37oC in nitrogen at different
synthesis reaction times. The reaction times with ethylenediamine (EDA) were 1 hour
(red), 2 hours (green), and 4 hours (blue). The same LED and stepwise voltage
increases seen in Figure 2.6 were used here. As the reaction time of EDA with PVC
increases, more crosslinking between the polymer chains occurs. This crosslinking
limits the amount of free amine sites to be reacted with NAP-thiolactone while also
causing the PVC to become a darker yellow color, limiting the release from the LED.
Total NO release was also determined for the polymer films with varied reaction times
to ensure that the 2 hour EDA reacted SNAP-PVC was the most optimized reaction
time to achieve the highest NO loading in the material. To do this, the three films were
all placed into a reaction chamber where a high intensity UV light was shined onto the
films until no visible NO release was detected. Figure 2.9 shows that the higher 4 hour
reaction time SNAP-PVC was releasing the lowest amount of NO while the 2 hour
reaction time SNAP-PVC released the highest. This displays the limit of NO release
that can be done using this method, as the crosslinking interferes too much passed a
certain amination point. This is further proven in Table 2.1, where the increase in
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ethylenediamine reaction time does show to increase the nitrogen content, but a
decrease in primary amines at the 4 hour reaction time. Further improvements could be
made to increase the capacity by using a self-protected aminating agent instead of a
difunctional aminating agent. This would allow the attachment of the reactive molecule
to the backbone of the PVC chains with no crosslinking. The polymer could then be
deprotected to expose the reactive group that could then be modified with SNAP.

Figure 2.9. SNAP-PVC compounds with varied reaction times in EDA with triggered
UV light photoinitiated for total NO release. The SNAP-PVC films were categorized
into 1 hour (blue), 2 hour (green), and 4 hour (red) reaction times with EDA. Films
were rinsed with DI water beforehand and vacuum dried to get rid of any excess nitrites
that could interfere with the testing. SNAP-PVC with the 2 hour reaction time proved to
have the highest NO storage capabilities while the higher 4 hour reaction time showed
the lowest. This further proves the crosslinking kinetics that occur when reacting a
polymer with a difunctional molecule over long periods of time.
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Table 2.1. FQ and CHN analysis on aminated PVC to observe the primary amine and
nitrogen content as reaction time with ethylenediamine increases. As the reaction time
with ethylenediamine increases, the amount of primary amines present decrease at the 4
hour reaction time point. From the CHN combustion data, there is an increase in
nitrogen content, proving the crosslinking of ethylenediamine to other polymer chains
the longer the solution is refluxed.
Sample

Primary amine

%N (by mass)

content (µmol/mg)
PVC 1 hour reaction time

0.0362±0.016

0.15

PVC 2 hour reaction time

0.201±0.013

0.167

PVC 4 hour reaction time

0.0188±0.0023

0.20

2.4 Conclusion
The synthesis of NO releasing SNAP PVC was successful and the flux of NO obtained
from the polymer was shown to release at a variety of physiological ranges. This could
greatly improve the potential applications for blood and tissue contacting PVC based
materials that are already used in medical settings. Depending on the degree of
amination and light intensity administered from specific LED wavelengths, SNAP-PVC
is able to be utilized to deliver specific controlled NO loading and release. The material
could also be applied used as implantable device coatings to improve biocompatibility
or to prevent neointimal hyperplasia of vessels. It could also be used as a base material
for catheters and other PVC related medical devices, extending the duration it is
allowed to stay in contact with tissue and blood before complications occur.
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Chapter 3 : High Capacity Nitric Oxide Release from
S-Nitroso-N-Acetyl-D-Penicillamine Modified
Hyperbranched Polyamidoamine (SNAP-HPAMAM)
for Controlled Nitric Oxide Release
3.1 Introduction
Nitric oxide (NO) has been proven to be an important molecule with multiple functions
such as maintaining vascular health, mediating inflammatory response, and preventing
bacterial adhesion depending on the level of NO that is being released1-3. To further the
advancement of biomedical devices and sensors, being able to mediate and reduce the
foreign body response of a patient is an important factor. For patients that are in critical
condition where an important analyte is constantly monitored, biosensors must be able
accurately measure it. Due to the foreign body response, these medical devices often
lose their functionality over a short period of time. NO has the ability to minimize
unwanted inflammatory response and increase the longevity of implantable medical
devices. The two most popular NO releasing materials to be applied in a medical
application are S-nitrosothiols and N-diazeniumdiolates4-5. These molecules are able to
be covalently attached to materials to provide stable, NO releasing compounds. The
release mechanisms of these and other NO donors have been well characterized6. Long
term NO release at a physiological level is necessary for keeping implantable devices
free from unwanted immune response, favoring the slower and more controlled release
mechanism of S-nitrosothiol chemistry. Using an NO donor with the potential for a
high NO reservoir, polymers would able to contain the amount of NO required for these
long term situations.

2

Dendrimers are highly branched, symmetrical macromolecules that can have a wide
array of surface chemistry characteristics. They start with a core molecule, and from
there can progress in size and functionality with stepwise reactions done in separate
2

Material in this chapter is in the process of being submitted for publication.
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batch processes. Several groups of researchers led by Buhlier, Newkome, and Tomalia
pioneered the development of dendritic type macromolecules to eventually lead to the
large field of dendrimer research that is seen today7-9. A similar class of macromolecule
to dendrimers are hyperbranched polymers. Hyperbranched polymers do not have the
symmetry that is seen with dendrimers, and are usually a large array of randomly sized
molecules as there are no purification or chromatography steps during the processing10.
Because of this, hyperbranched polymers act more like synthetic polymers as they have
a large molecular weight distribution of different sized chains, whereas perfectly
synthesized dendrimers only contain a single mass to be observed11. Dendrimers and
hyperbranched molecules have the ability contain a large reservoir of NO due to the
large amount of surface functional groups they contain. Dendrimers have been widely
used in medicine and are continuing to grow in popularity due to its molecular storage
capabilities and high functionality12. They are used in a variety of medical applications
such as cancer treatments, gene therapy, and precise drug delivery12-15. A popular class
of dendrimer that is widely used in research is polyamidoamine (PAMAM). PAMAM
dendrimer and hyperbranched polymer cytotoxicity has been previously investigated
and found that the main mechanism for which these molecules decrease cell viability is
through cationic disruption of cell plasma membranes16,17. By modifying the primary
amine sites with SNAP functional groups, PAMAM dendrimers have been shown to not
negatively affect the cells they interacts with18.
NO releasing dendrimers have been tested before by Stasko et al. to demonstrate the
NO storage capability of this type of molecular architecture19. The authors were able to
fully characterize 64 armed dendrimers with the ability to deliver large, precise amounts
of NO. While this type of NO releasing molecule is excellent for targeted therapeutics,
it is limited in its role for integrating into polymer matrices. The synthesis route for
creating high generation dendrimers takes a large amount of labor and time due to the
extent of the purification processes required. Hyperbranched polymers are similar to
dendrimers but contain defects within the structure due to skipping these purification
process steps during synthesis20. Hyperbranched polyamidoamine (HPAMAM)
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molecules can be synthesized in a simple and economical method as a high yield of
product is obtained over a shorter period of time is compared to pure PAMAM
dendrimers. The importance of the compound is stressed on the functional groups more
than the dendritic structure when looking into high capacity, blendable NO donating
materials. The significantly reduced reaction times and purification steps make these
highly functionalized hyperbranched polymers attractive for use as an NO delivery
vehicle to be blended into various polymeric matrices to develop a range of NO
releasing materials, simply by varying the amount of donor blended into the base
polymer.
NO releasing hyperbranched polyethers have been previously synthesized using Ndiazeniumdiolate NO donors, but have shown poor NO addition efficiency21. Ndiazeniumdiolate molecules also do not have the controllability as seen with SNAP
based NO donors as its release mechanism is triggered when put in physiological pH
and temperature22. The purpose of creating a SNAP-HPAMAM compound is to use to
blend within other polymers while still maintaining all of the beneficial properties of a
SNAP based NO donor, giving the option of either having a controlled or passive
release of NO.
Herein, HPAMAM was modified with the S-nitrosothiol, N-acetyl-D-penicillamine, and
nitrosated to form a controlled NO donating compound (SNAP-HPAMAM). This
compound was triggered to release NO by photoinitiation and ion mediated release.
Structural analysis of a generation 1 HPAMAM molecule was done through FTIR, 1H
NMR, and MALDI-TOF mass spectroscopy. The NO capacity of a generation 1 SNAPHPAMAM molecule ended up being approximately 1.90 µmol NO/mg. Quantification
of the functional groups in the compound proved that an average of 6.40 reactive
primary amine sites per molecule were present compared to the 8 reactive sites on a
perfectly synthesized generation 1 dendrimer.

3.2 Experimental Details
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3.2.1 Materials
Ethylenediamine, methyl acrylate, methanol, ethanol, toluene, pyridine, acetic
anhydride, chloroform, hexanes, hydrochloric acid, magnesium sulfate, α-cyano-4hydroxycinnamic acid, Lugol’s iodine, glacial acetic acid, Ellman’s reagent were all
purchased from Sigma Aldrich (St. Louis, MO, USA). ATTO-TAG FQ reagent was
purchased from Invitrogen (Grand Island, NY, USA). Tert-butyl nitrite (90% technical
grade, Acros Organics) was purchased from Fisher Scientific.
3.2.2 Synthesis of HPAMAM
Generation 1 HPAMAM molecules were synthesized following a modified procedure
previously done23. The core molecule to initiate the hyperbranched polymer was 83
mmol of ethylenediamine (EDA), which was dissolved in 250 mL of methanol and
cooled in an ice bath. 340 mmol of methyl acrylate (MA) was added drop wise to the
stirring solution of EDA and methanol. The solution was then allowed to stir at room
temperature for 48 hours. The methanol and unreacted MA was removed by rotary
evaporation at 45oC to yield a four armed ester terminated hyperbranched polymer. 742
mmol of EDA was dissolved in 100 mL of methanol in a separate container and chilled
in an ice bath. This solution was then added drop wise to the stirring ester terminated
hyperbranched polymer and allowed to stir at room temperature for 72 hours. Rotary
evaporation was then done to remove the most of the unreacted EDA and methanol at
45oC. Excess EDA was removed by adding a toluene and methanol mixture with a ratio
of 9:1 (v/v) respectively at its temperature azeotrope to yield a four armed amine
terminated molecule (generation 0 HPAMAM).
The same reaction process was then repeated where MA in two times molar excess is
dissolved in 100 mL of methanol and added drop wise to the chilled generation 0
HPAMAM and allowed to stir for 48 hours at room temperature. Repeating the EDA
reaction step and removal method results in an eight armed amine terminated molecule
(generation 1 HPAMAM). The solution becomes noticeably more viscous and amber in
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color after each step. The reaction schematic and final product formed is shown in
Figure 3.1.
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Figure 3.1. Synthesis schematic of hyperbranched polyamidoamine (HPAMAM).
Ethylenediamine is used as the core starting molecule, and is then propagated through
the Michael addition of methyl acrylate. The process is then repeated until the desired
hyperbranched structure is created.
3.2.3 Synthesis of NAP-thiolactone
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The procedure described in section 2.2.2 was used for the synthesis of NAP-thiolactone
and its reaction scheme is seen in Figure 2.1.
3.2.4 Nitrosation of N-acetyl-D-penicillamine modified HPAMAM
There are two methods that can be employed to nitrosated HPAMAM. Using acidified
nitrites as a nitrosation pathway was done for the first method. The synthesized
generation 1 HPAMAM (400 mg) was dissolved in 5 mL of deionized water. 3.00
mmol (519 mg) of NAP-thiolactone was added to the stirring solution and was allowed
to react for 24 hours to form a NAP-HPAMAM compound. An additional 5 mL of
deionized water may need to be added to ensure all of the NAP-thiolactone is dissolved.
The NAP-HPAMAM solution that is formed was mixed with an equal volumetric
amount of 1M hydrochloric acid and chilled in ice for one hour. An abundance of
sodium nitrite (230 mg, 3.33 mmol) was then added to the solution and allowed to react
at 0oC for 45 minutes. As the reaction occurs, the color will change from clear/light
yellow to a dark green. The solution was then rotary evaporated at room temperature
until most of the solvent is removed. The resulting SNAP-HPAMAM was then
dissolved in chilled ethanol and mixed thoroughly. The ethanol solution was filtrated of
any excess sodium nitrite or unreacted precipitates using 0.22 µm PVDF syringe filters.
The SNAP-HPAMAM ethanol solution was rotary evaporated at room temperature until
a green viscous precipitate is left. This precipitate was then placed in a vacuum oven at
room temperature until the green viscous product is completely dried. The resulting
crystalline product can then be recovered and stored. Shielding the compound from
light was maintained during all processing steps whenever possible.
The second method uses tert-butyl nitrite for nitrosating the NAP-HPAMAM.
Generation 1 HPAMAM (400 mg) is dissolved in 5 mL of methanol and the same
amount of NAP-thiolactone is added as was previously mentioned. The solution was
then allowed to react for 24 hours. 1M HCl was then added to the NAP-HPAMAM until
the pH of the solution is approximately 5.0. The resulting NAP-HPAMAM methanol
solution is then reacted with tert-butyl nitrite in excess (500 µL, 4.84 mmol). Before
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adding the tert-butyl nitrite, it was first cleaned by using 30 mM cyclam (1,4,8,11tetraazacyclotetradecane) to chelate any metal ions present that could cause RSNO
degradation. After the addition of the cleaned tert-butyl nitrite to the NAP-HPAMAM,
the solution should change from clear/light yellow to a deep green color over the course
of an hour. To remove the excess solvent, it was rotary evaporated at 35oC and then
vacuum dried at room temperature to obtain a crystalline product. For situations where
your compound would need to be kept in the aqueous phase during reacting or blending
with other materials, utilizing the acidified sodium nitrite method is preferred. Using
tert-butyl nitrite to nitrosate the NAP-HPAMAM is the preferred method for when
working with organic solvents. When isolated and dried, the tert-butyl nitrite nitrosated
SNAP-HPAMAM looked a much deeper green color when compared to the first
method that uses sodium nitrite. This could be due to the less steps of processing that is
required, preventing the exhaustion of NO in the material over time.
3.2.5 Nitric oxide release
Nitric oxide released from the compound was directly measured by the
chemiluminescent reaction of NO with ozone using a Sievers 280i Nitric Oxide
Analyzer (GE Instruments). This was used to determine the variation of NO flux from
polymer films containing SNAP-HPAMAM with light and for determining the total NO
capacity of SNAP-HPAMAM. SNAP-HPAMAM was cast into films using polyvinyl
chloride (PVC) as the base polymer. For determining photoinitiated NO release, the
films were placed in a two armed amber glass sample holder 5 cm above a mounted
LED. The LED was used to trigger the NO release at a variety of voltage levels at 130
Ω to show the controllability of SNAP based NO donors.
NO capacity quantification was achieved by tri-iodide reduction following the
procedure from Yang et al24. An I3- solution was first made by creating a 3% by weight
iodine solution and mixing it with acetic acid in a 2:7 ratio by volume respectively. A
recorded weight of SNAP-HPAMAM was first pre-treated with a 5% acidified
sulfanilamide solution to react with any unreacted nitrites that could be. After allowing
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the I3- solution to stir for 30 minutes, it was added to the measured SNAP-HPAMAM
while being stirred at room temperature.

Figure 3.2. Schematic of SNAP-HPAMAM’s generic structure and triggered NO
release methods. The hyperbranched system shows a disorganized but highly
functionalized network capable of storing large amounts of NO by attaching SNAP to
the reactive end groups in the HPAMAM structure. The NO can be triggered through
light, ion interaction, and heat.
3.2.6 Material characterization
FTIR, NMR, and MALDI-TOF mass spectroscopy were done to obtain the general
structure of the HPAMAM and NAP-HPAMAM molecules being synthesized.
Quantification of primary amines was accomplished using by fluorescently tagging each
site with ATTO-TAG FQ. Excitation was at 450 nm while the emission wavelength was
at 550 nm. After each free primary amine site was reacted with NAP-thiolactone,
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Ellman’s test for free thiols was done to quantify the conversion of amines to thiols
within the hyperbranched structures. Optical absorbance was taken at 412 nm using a
96-well plate reader. The quantified results were then used to further verify the
hypothesized structures obtained from the FTIR and MALDI-TOF data.

3.3 Results and Discussion
3.3.1 Photoinitiated nitric oxide release
One of the main mechanisms for controlled release of NO from RSNOs is through
homolytic cleavage of the sulfur-nitrogen bond via the administration of light. In the
dark, the SNAP-HPAMAM material is stable while at room temperature, but can have a
controlled and stable release of NO when different levels of light are introduced. The
stability translates to the NO release profiles seen in Figure 3.3, where SNAPHPAMAM was distributed evenly into PVC thin films and tested. The control in NO
release is seen by photoinitiated release at various intensities of light using a 470 nm
wavelength LED at 130Ω. Voltages are adjusted to increase or decrease the drive
current applied to the LED and the then turned off to demonstrate the time to takes to
reach a normal baseline release. Once the peak level of NO release is reached for each
LED flux step, there is little to no decay. The benefit of having a controllable NO
releasing material is the application for in vitro testing. Different cell types interact with
specific levels of NO in different ways. Most in vitro testing of NO administration is
usually done by adding a solution of N-diazeniumdiolates NO donor directly to cell
media. This method only gives a short lived burst of NO before being diminished. NO
contact with cells usually comes in the form of a flux, where a constant and steady level
of NO is released over time. Using the light sensitive properties of RSNOs, an in vitro
cell culture setup could have a level flux of NO sent to the cells over a long period of
time.
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Figure 3.3. NO release profile of SNAP-HPAMAM blended in PVC using
photoinitiation. Samples were placed in amber, two armed vials with a nitrogen sweep
gas where a 470 nm LED was mounted 5 cm above the polymer film being tested. The
resistance was held constant at 130Ω while the voltage was increased and decreased in
increments of 1.5V, starting from 3V. Before each step increase, the LED was turned
off to demonstrate the controllability photoinitiated NO release contains. The films were
5.5 mm in diameter and 0.1 mm thick.
3.3.2 Ion mediated nitric oxide release
The SNAP-HPAMAM that was used for photoinitiated NO release was also tested for
its passive release from ions. SNAP has the ability to release NO from a variety of
different ions in solution such as copper, ascorbate, and iron4. Using the SNAPHPAMAM that was nitrosated using the acidified sodium nitrite mechanism, multiple
ion mediated release pathways were tested. 2.16 mg of SNAP-HPAMAM was placed
in PBS at 37oC to give a representative NO release profile under in vivo conditions and
is shown in Figure 3.4. In aqueous conditions, SNAP-HPAMAM tends to swell and
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dissolve readily. The large peak of NO release seen once the PBS is added can be
explained by the ubiquitous transition metal ions present in PBS initiating catalytic
decomposition of the RSNOs present.

Figure 3.4. Passive NO release from 2.16 mg of SNAP-HPAMAM in 2 mL of PBS at
37oC. The material was first placed into a two armed amber reaction vessel and allowed
to warm to temperature. PBS was added at 37oC to observe how NO is released from
SNAP-HPAMAM while under physiological conditions.
SNAP-HPAMAM is stable when blended into films with other hydrophobic
polymers and is able to retain the NO donating group for longer periods of time by
decreasing the access of transition metal ions to the RSNOs compared to directly
administering it into solution. Figure 3.5 shows how this method increases the
longevity of the NO donor when 6 mg of SNAP-HPAMAM were blended with a
solution of PVC dissolved in N,N-dimethylacetamide and cast into 10 mm diameter
films. If a hydrophilic polymer like polyvinyl alcohol was used instead, it would allow
the uptake of water and eventually the release of the immobilized SNAP-HPAMAM
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into the surrounding area as it swells. This would cause problems as the localized NO
release would no longer be controllable. To prevent this, PVC was used as the polymer
containing SNAP-HPAMAM due to its properties as a membrane for ion-selective
electrodes25. Other hydrophobic polymers like polydimethylsiloxane (PDMS) further
prevent ion diffusion into the polymer compared to PVC, and would be suitable for
situations where only thermal degradation of the RSNO is required. PVC gives the
option of using ion mediated NO release of the SNAP functional group while still
having the option of a more controlled release through a photolytic response. A
characteristic seen with blending SNAP-HPAMAM within PVC is its abilty to act like a
plasticizer. Unplasticized PVC tends to be quite brittle but still manageable when cast
into thin films. SNAP-HPAMAM PVC is less brittle than pure PVC, and has more
elastic properties when the concentration within the polymer matrix is high enough.
Hyperbranched polyesters have been known to be suitable, safe plasticizers in PVC26.
The unreacted, defected ester branches see in HPAMAM are most likely providing a
similar plasticizer property seen in the hyperbranched polyester blends.
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Figure 3.5. Passive NO release of 6.01 mg of SNAP-HPAMAM encapsulated in PVC
in PBS at 37oC. When compared to Figure 3.4, the encapsulation of the material shows
an increase in longevity as a high release of NO is able to be sustained over a longer
period of time. Preventing the NO donor from leaching out of the polymer matrix
allows for very long term, sustained release dependent on the amount of material loaded
within the polymer.
Other hydrophobic polymers can be used as well to give off different release
profiles of SNAP-HPAMAM while in PBS. To demonstrate this versatility, multiple
polymers were blended with the same amount of SNAP-HPAMAM and then placed
under physiological conditions. This comparison between the polymers is shown in
Figure 3.5. The ion diffusion capability of PVC is proven here as it demonstrates the
highest amount of NO release. Other materials such as RTV-3140 do not show as high
of a release, but are able to release at a steady flux over a long period of time.
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Figure 3.6. Passive NO release in PBS at 37oC from multiple polymers blended with
SNAP-HPAMAM. 10 mg of SNAP-HPAMAM was blended into multiple films (15
mm diameter). This shows the flexibility of SNAP-HPAMAM blended hydrophobic
polymeric systems as the amount of NO over time can be adjusted based on the polymer
properties it is immobilized in. PVC (orange) showed the highest passive release when
placed in PBS along with a decent amount of release seen in PLLA (blue). SNAPHPAMAM blended in RTV-3140 (gray) showed the lowest amount of release due to its
ability to prevent ion diffusion, but demonstrates a very steady release profile which can
still be useful in specific situations.
3.3.3 FTIR analysis
Identification of the important functional groups of the HPAMAM compound was seen
in the FTIR data collected seen in Figure 3.7. The presence of primary amines seen in
the HPAMAM spectra is seen around the 3300 cm-1 range (N-H stretching) and 1620
cm-1 (N-H bending), which are then removed once the attachment of NAP-thiolactone is
added, which reacts with primary amine groups. The important note of transition from
NAP-HPAMAM to SNAP-HPAMAM is the disappearance of the thiol peak at 2550
cm-1 once it is nitrosated, showing an efficient addition of the NO group to the
compound. The NO peak is difficult to see due to the presence of the large amount of
amides in the structure, which contain carbonyl groups at roughly 1500 cm-1. Nitroso
peaks are also commonly seen in this range.
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Figure 3.7. FTIR spectrum of hyperbranched compounds. Demonstrates the
progression of HPAMAM (green), NAP-HPAMAM (blue), and SNAP-HPAMAM (red)
compounds. The N-H stretches from primary amines are visible around the 3300-3400
cm-1 range for HPAMAM which then disappears when NAP-thiolactone is attached.
Once NAP-HPAMAM is formed, a free thiol peak is seen at 2550. This thiol is then
nitrosated as the peak is no longer present when it is nitrosated to form SNAPHPAMAM.
3.3.4 NMR analysis
NMR was also done on the base HPAMAM compound to verify the initial synthesis
procedure is producing the correct dendritic structure. The important characteristic
functional groups seen in PAMAM dendrimers were classified within the NMR
spectrum. 1H NMR (400 MHz, CDCl3): δ 7.47 (7H, CONHCH2, t), 3.41 (4H, COOCH3,
s) 3.23 (14H, NHCH2CH2, q), 2.70 (13H, CH3CH2N, t), 2.63 (11H, CH2CH2NH2, quin),
2.31 (19H, CH2CH2CO, t), 1.36 (22H, CH2NH2, s). The presence of unreacted ester
groups and non-amide containing branches are present, but the primary amine groups
remain abundant in the overall hyperbranched structure.
3.3.5 Quantification of thiols and primary amines
Quantification of the important functional groups was done by attaching the fluorescent
tag ATTO-TAG FQ (3-(2-furoyl) quinoline-2-carboxaldehyde) to the primary amine
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sites present on the HPAMAM molecule following the procedure developed by Liu et
al.27. The amount of free primary amines present in the compound was calculated to be
4.48±0.22 µmol/mg, which gives an average of 6.40±0.31 amines per HPAMAM
molecule. A perfectly synthesized generation 1 PAMAM dendrimer would contain 8
primary amines per molecule. Using this hyperbranched synthesis route, there was
proven to be not a large loss of amine functionality in the compound.
Ellman’s test for free thiols was then used to quantify the amount of thiols present after
attaching the synthesized NAP-thiolactone compound to the free primary amines
following a modified protocol developed by George Ellman28. PBS (pH = 7.4) was used
in place of Tris-buffer for the procedure as any excess unreacted NAP-thiolactone can
react with the primary amine functional groups present in the Tris-buffer. The amount
of free thiols found using the assay was found to be 2.74±0.30 µmol/mg.
3.3.6 Nitric oxide capacity testing
Total NO capacity of SNAP-HPAMAM was done through tri-iodide reduction and was
compared to the amine and thiol quantification values. A perfectly synthesized 8 armed
SNAP derivatized PAMAM dendrimer has the capability to release 5.594 µmol of NO
per mg if every primary amine functional group was modified to a SNAP functional
group. Hyperbranched polymers contain defects within the structure, so the amount of
NO release will be somewhat lower. Since the average amount of free amines are
known from the FQ test, the theoretical max conversion of primary amine sites to
SNAP should be similar. The synthesized SNAP-HPAMAM demonstrated a capacity of
1.90±0.12 µmol of NO/mg. Comparing the amount of NO released with the theoretical
max gives a 69.4% molar conversion of NAP-HPAMAM to SNAP-HPAMAM, but
only a 42.4% molar conversion of HPAMAM to SNAP-HPAMAM. Compared to the
SNAP-PVC previously described which only had a capacity of approximately 0.0392
µmol of NO/mg, this is a significant increase in loading potential. The conversion
percentage is low most likely due to the processing steps for isolating the material.
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Attaching the NAP-thiolactone to all of the free primary amine arms is quite difficult in
a hyperbranched network as there is an abundant of steric hindrance present. During the
nitrosation and isolation of SNAP-HPAMAM, the vacuum drying and rotary
evaporating steps can take a lot of time. Keeping SNAP-HPAMAM in solution during
these steps could be causing passive release, lowering the NO capacity of the final
solid-phase product in the end.
3.3.7 MALDI-TOF analysis
Figure 3.8 and Figure 3.9 show the MALDI-TOF analysis done on the synthesized
HPAMAM and NAP-HPAMAM compounds respectively. α-Cyano-4-hydroxycinnamic
acid (CHCA) was the matrix used for all tests. Since MALDI-TOF is a softer ionization
mass spectroscopy technique, there is no fragmentation occurring during testing. This
means that the entire range of peaks seen is a specific hyperbranched molecule with its
own branching chemistry.

Figure 3.8. MALDI-TOF analysis of HPAMAM. Each labeled peak signifies the
addition of a 229 Da amine containing branch to the polymer, where a 4 armed
HPAMAM molecule is at 516 Da, 5 armed at 745, etc. This gives an insight into the
distribution of hyperbranched molecules within the synthesized HPAMAM batch.
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Figure 3.9. MALDI-TOF analysis of NAP-HPAMAM. Each labeled peak signifies the
addition of a NAP containing branch site on the polymer, where a 4 armed NAPHPAMAM is at 1207 Da, 5 armed at 1606 Da, etc. The 229 Da amine containing
branches have an extra 173 Da added to them, increasing addition of a reactive arm to
approximately 402 Da.
A wide range of mass peaks was seen as there are unreacted components still present as
the synthesis process of the HPAMAM progresses. The spectra of the materials are
characteristic of polymers, where each increment signifies a repeat unit. The spectrum
of HPAMAM shows the molecular weight of multiple different branched polymers. The
4 armed HPAMAM starts at a mass of 516 Da and is increased by increments of 229 Da
with the addition of another branched functional group. Mass peaks past 1430 Da,
which is the 8 armed HPAMAM, are most likely due to HPAMAM molecules attaching
to each other. The second spectrum shows the attachment of NAP-thiolactone to free
primary amine site branches in HPAMAM. The molecular weight of NAP-thiolactone is
173.23 Da, so the 229 Da mass increments between peaks seen in figure 6 are increased
to approximately 402 Da for each additional HPAMAM branch. An example of one of
the NAP branched hyperbranched structures is shown in Figure 3.10. Each peak seen
on both MALDI-TOF spectra can be used to construct some variation of the modified
HPAMAM structure. The peak molecular weight of the HPAMAM spectrum is seen at
the 973 Da mark, which is the weight of a 6 armed PAMAM structure. This is also
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confirmed by the ATTO-TAG FQ results which gave an estimated 6.40 primary amine
sites per HPAMAM molecule.
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Figure 3.10. Structure of 6 armed NAP-HPAMAM (Mw = 2413.14 Da). This specific
molecular weight from MALDI-TOF is seen in Figure 3.7 and represents the 6 armed
NAP branched HPAMAM. Similar structures can be constructed for each peak
represented in the MALDI-TOF spectra.

3.4 Conclusion
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SNAP-HPAMAM was able to show excellent stability and controllability when
releasing NO. The synthesis process is shown to be much less tedious than that of
dendrimers while still maintaining a relatively high functionality. A large NO capacity
of 1.90 µmol/mg was demonstrated, allowing SNAP-HPAMAM to modify a variety of
polymers to be high capacity NO donating biomaterials by simply dispersing it within a
polymer matrix. These high capacity NO releasing polymers can then be applied to
implantable devices and sensors to increase their longevity while measuring crucial
analytes in vivo.
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Chapter 4 : Subcutaneous Inflammatory Response to
Polyvinyl Chloride Based Nitric Oxide Releasing
Materials
4.1 Introduction
Implantable medical devices can be of vast importance when patients in critical care
require constant monitoring of important analytes like glucose or oxygen. These long
term implanted devices lose their functionality over time due to the foreign body
response. Depending where the device is implanted, whether it is in contact with blood
or tissue, the body will begin to reject and isolate it1. For blood contacting devices,
proteins will immediately adhere to the surface. This then allows platelets to attach to
the device interface and become activated. Once platelet activation occurs, the
formation of fibrin leads to a fibrous clot, which has a risk of breaking off and causing
an embolism.
Tissue contacting devices have a different foreign body response. In the example of
subcutaneous implants, mast cells will first degranulate and release histamine and other
cytokines to allow the migration of neutrophils and blood monocytes to the area2. This
response is fairly quick, and is done within minutes-hours of the initial implantation.
The migrated monocytes then differentiate into macrophages to attempt to phagocytize
the foreign material and bacteria that may be present. If the wound healing is not
resolved, frustrated phagocytosis occurs as large implanted biomaterials cannot be
properly phagocytized compared to bacteria. Eventually the macrophages begin to fuse
together to form foreign body giant cells (FBGCs). FBGCs release harsh degradative
enzymes and reactive oxygen species as they continue to at 3tempt to break down the
implanted biomaterial3. This can be problematic for materials with delicate surface
chemistry as a large drop in pH at the FBGC-material interface is seen4. Fibrous
encapsulation will then begin after FBGCs are unable to phagocytize the foreign
3

Material in this chapter is in the process of being submitted for publication.
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material, where a collagenous capsule is formed in an attempt to isolate it off from the
rest of the surrounding tissue5. For an implanted sensor, this encapsulation causes
incorrect readings in the monitored analyte. The foreign body response to implanted
biopolymers shows poor biocompatibility when in contact with tissue or blood.
Utilizing the anti-inflammatory properties of NO, this unwanted response from the body
can be mediated and moved to the resolution phase of wound healing more rapidly.
NO is a free radical signaling molecule produced in the body with a wide range of
important functions like smooth muscle relaxation, thromboresistivity, and as an antibacterial agent6-9. Macrophages are known to produce NO through inducible nitric
oxide synthase (iNOS) as the mechanism for killing foreign bacteria10. It is also an
important molecule for mediating and controlling the inflammatory response11. Using
these properties, NO releasing materials have been developed to help prevent unwanted
inflammatory responses. A popular NO donor that is able to release its NO reservoir
under physiological conditions are N-diazeniumdiolates (NONOates)12. This type of
NO donor is convenient when administering a short, but precise amount of NO when
implanted. Subcutaneous implanted xerogels doped with NONOates have been
previously reported to lower the chronic inflammatory response along with reducing the
fibrous encapsulation thickness over a 6 week period around an implant13. This
demonstrates how even a short term administration of NO can have long term and
beneficial effects. Subcutaneous sensors that measure glucose are critically important
for diabetic patients, but the in vivo longevity is shortened by the foreign body
response14. The NO donor to be used for this study is S-nitroso-N-acetyl-Dpenicillamine (SNAP), an S-nitrosothiol capable of releasing controlled amounts of NO
when in contact with light, specific metal ions, and heat. The passive release seen from
SNAP donors are much lower than NONOates when placed under physiological
conditions, but in turn are able to release for longer periods of time.
Two different types of NO releasing SNAP based PVC materials were implanted
subcutaneously for 1 and 15 days to observe NO’s effect on the initial stages of
inflammation and its transition into a chronic inflammatory state. The first PVC
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polymer covalently links an NO donating material to the backbone of the polymer
(SNAP-PVC) while the second PVC polymer blends a nitrosated hyperbranched
polyamidoamine NO donor within the polymer matrix (SNAP-HPAMAM). Each
material gives its own distinct NO release profile when under physiological conditions
to observe how the inflammatory and wound healing responses are effected by the
presence of different administrations of NO.
The inflammatory responses that were investigated were the quantity and phenotype of
macrophages present, total cell count, mast cell degranulation, and the fibrous
encapsulation around the implant area. The two macrophage phenotypes that were
observed were M1 (classically activated) and M2 (alternatively activated) macrophages.
M1 macrophages encourage chronic inflammation to a foreign substance while M2
macrophages decreases the inflammatory response while encouraging tissue repair and
remodeling15-16. Counting the number of macrophages present does not give an accurate
representation of the state of inflammation of an implanted material. Observing the ratio
of M1 to M2 macrophages that are around the implant site would be able to demonstrate
if NO is able to resolve chronic inflammation around an implant. This would then be
able to give more insight into how the administration of certain levels of NO can be
utilized to benefit long term implanted biomedical devices.

4.2 Experimental Details
4.2.1 Materials
Methanol, ethanol, methyl acrylate, ethylenediamine, polyvinyl chloride (average Mw =
233,000, Mn = 99,000), 5, 5’-dithiobis (2-nitrobenzoic acid), triethylamine, N,Ndimethylacetamide, goat serum, Lugol’s iodine solution, 1,4,8,11tetraazacyclotetradecane, N-acetyl-D-penicillamine (Fluka), Polyfreeze medium, bovine
serum albumin in PBS, and concentrated hydrochloric acid were obtained from SigmaAldrich (St. Louis, MO, USA). Tert-butyl nitrite (90% technical grade, Acros Organics)
was purchased from Fisher Scientific. Magnesium sulfate, copper (II) bromide, L81

ascorbic acid sodium salt, and acetic anhydride (Alfa Aesar) were purchased from
VWR (West Chester, PA, USA).
For the antibodies, anti-CD11b mouse monoclonal antibody, biotinylated goat anti
mouse IgG, endogenous avidin/biotin blocking kit, and Alex Fluor 633 streptavidin was
purchased from Abcam (Cambridge, MA, USA). Anti-CD163 mouse monoclonal
antibody was purchased from Santa Cruz Biotech (Dallas, TX, USA). iNOS rabbit
polyclonal antibody (PA3-030A), ATTO-TAGTM FQ, and goat anti-Rabbit Alexa Fluor
488 (A-11034) were purchased from Thermo Fisher Scientific (Grand Island, NY,
USA).
Staining reagents included Eosin Y disodium salt, acetic acid (99.7%), Toluidine Blue
(powdered), phosphotungstic acid solution 10% w/v, phosphomolybdic acid hydrate
solution, Biebrich scarlet acid-fuchsin solution, Analine blue solution, absolute ethanol,
xylene substitute, Gill No. 3 hematoxylin solution, Hematoxylin (powdered), anhydrous
Iron (III) chloride (powder 99.99%), Lugol’s iodine Solution, and Eukitt quickhardening mounting medium; all were obtained from Sigma Aldrich.
4.2.2 Synthesis of self-protected N-acetyl-D-penicillamine (NAP) thiolactone
The synthesis procedure of NAP-thiolactone was described in chapter 2 following the
procedure developed by Moynihan and Robert17.
4.2.3 Synthesis of SNAP-PVC
The detailed procedure for synthesizing SNAP-PVC has been described previously in
chapter 2. Primary amine groups are first attached to PVC to form an aminated PVC
compound which is described by Tinkilic et al18. Briefly, PVC is suspended in methanol
along with ethylenediamine and triethylamine and is refluxed at 60oC for 2 hours then
filtered. The resultant aminated PVC can then be reacted with NAP-thiolactone to allow
a free thiol group to be nitrosated by t-butyl nitrite.
82

4.2.4 Synthesis of SNAP-HPAMAM
The synthesis procedure for SNAP-HPAMAM was described in more detail previously
in chapter 3. The core hyperbranched molecule followed a modified procedure
popularly used for developing polyamidoamine (PAMAM) dendrimers19.
Ethylenediamine dissolved in methanol was used as the core molecule. Methyl acrylate
was then added slowly to give a 4 armed, ester terminated molecule. The solution was
rotary evaporated until a viscous product was yielded, and dissolved into methanol once
again. Ethylenediamine was then added to give a 4 armed amine terminated molecule.
The process is then repeated until a generation 1, 8 armed amine terminated molecule
was formed. Each of the primary amine groups was then reacted with NAP-thiolactone
and nitrosated with t-butyl nitrite to form SNAP-HPAMAM.

4.3 Characterization
Both materials, SNAP-PVC and SNAP-HPAMAM, were characterized using FTIR,
MALDI-TOF and NMR. The nitrosated compounds were tested for total NO capacity
using tri-iodide reduction. Further quantification was also done on the polymers to
verify the presence of important functional groups as the synthesis steps progress. The
two main functional groups were identified were primary amines and thiols. ATTOTAG FQ tested for primary amines for the HPAMAM and aminated PVC compounds,
and Ellman’s test for free thiols once NAP-thiolactone was covalently attached to the
amine sites. The characterization results for both of the materials have been covered
more in depth previously in chapters 2 and 3.
4.3.1 Nitric Oxide Release
NO release was recorded continuously through a Sievers 280i nitric oxide analyzer
(NOA) by chemiluminescence. Determining the NO capacity of the materials was done
by tri-iodide reduction following a protocol developed by Yang et al.20.
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4.3.2 Polymer Film Casting and Implantation Procedure
The solutions used to make the polymer films contained 2 weight % PVC and SNAPPVC while SNAP-HPAMAM was blended into a solution of PVC at 13 mg/mL. Both
SNAP based polymers were encapsulated with thin layers of PVC to prevent any
unwanted diffusion of SNAP-HPAMAM into the surrounding tissue after implantation
and to ensure the material contacting the tissue was consistent with the control polymer.
All of the materials were dissolved in N,N-dimethylacetamide and cast into films under
low humidity conditions. PVC, SNAP-PVC, and SNAP-HPAMAM PVC were then cut
into 10mm diameter films with an average thickness of 0.1mm. The materials were
implanted subcutaneously away from the initial incision site into four Sprague-Dawley
rats. Implantation procedures were approved by Michigan Technological University’s
Internal Animal Care and Use Committee (IACUC).
4.3.3 Hematoxylin and Eosin
Hematoxylin and eosin was used to observe the cell morphology and infiltration around
the surrounding implants along with collagen formation. After formalin fixation, slides
were washed with three changes PBS for 5 minutes. The slides were then rinsed with
deionized water for 5 minutes. Gills-3 Haematoxlin solution was added onto each slide
for approximately 2-5 minutes until overstained. Specificity of the Gills-3 staining was
done by dipping the slides into an acidified solution of HCl and distilled water (pH =
1.8-2.0) five times. The slides were then rinsed in 95% ethanol solution. Eosin Y
working solution (0.25%) was used as a counter-stain and was placed onto the slides for
45 seconds. They were then dehydrated in two changes of absolute ethanol for 5
minutes each and cleared twice with xylene substitute for 5 minutes. The slides were
mounted using Eukitt mounting medium and then imaged once dried.
4.3.4 Masson’s Trichrome
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Detection of fibrous collagen content was accomplished by using Masson’s trichrome
stain. This stain allows for accurate measurement and recognition of the collagen
fibrous capsule around the implant area. Weigert’s iron hematoxylin solution was first
prepared by dissolving 1g of hematoxylin in 100 mL of 95% ethanol. A separate
solution containing 29% w/v/ ferric chloride in deionized water was made and 4 mL
was added to 95 mL of deionized water and 1 mL of 1M HCl. The slides were
thoroughly rinsed with deionized water to remove any excess formalin and Polyfreeze
medium. Once rinsed, the slides were placed in the working Weigert’s iron hematoxylin
for 5 minutes and rinsed in running tap water for 15 minutes and then rinsed with
deionized water. Bierbrich scarlet acid fuschin solution was placed on the slides for 10
minutes and differentiated using an equal parts mixture of phosphomolybdic and
phosphotungstic acid until the adventitial collagen in the tissue sections no longer
appeared red. The slides were then placed in aniline blue solution for 10 minutes and
rinsed in distilled water for 2 minutes. Differentiation was done by placing the slides in
a solution of 1% acetic acid and checked microscopically to determine staining
efficiency. A quick dehydration in 95% ethanol and absolute ethanol was done before
clearing in xylene and mounted.
4.3.5 Toluidine Blue
Mast cells surrounding the implant area were identified by toluidine blue. Activated
mast cells can be observed through the degree of degranulation and is stained purple. A
stock solution was prepared by dissolving 1g of toluidine blue in 70% ethanol. The
working solution contained 5 mL of the stock solution in 45 mL of 1% sodium chloride
solution with an adjusted pH of 2.4 using 1M HCl to adjust. Slides were hydrated in
three changed of deionized water for 5 minutes each and placed in the working solution
for 5 minutes. They were then dipped 3 times in 95% ethanol and 5 times in 100%
ethanol to dehydrate. Once dehydrated, the slides were dipped 20 times in a solution
containing 50% acetone and 50% xylene and then followed up by dipping them 20
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times in a solution containing pure xylene before mounted in resinous mounting
medium.
4.3.6 Immunofluorescence
A modified protocol from Abcam was used to prepare and label the tissue sections.
CD163 and iNOS antibody markers were used to differentiate between M2 and M1
macrophages respectively. Total inflammatory cells were quantified by using CD11b.
To enhance the signal, streptavidin-biotin antigen detection was employed after the
primary antibody markers were attached to the tissue sections. DAPI was then used to
label cell nuclei and verify the presence of macrophages.
For CD11b and CD163 staining, frozen sections were first allowed to warm to room
temperature from -80oC before being fixed in 10% formalin solution for 10 minutes.
The slides were then washed in three changes of PBS for 5 minutes each and then
placed in a solution of PBS containing 0.05% TWEEN 20 for 30 minutes. After these
washing steps, avidin blocking solution was placed onto the sections for 15 minutes and
then washed in 2 changes of PBS for 5 minutes each. The same procedure was then
repeated for the biotin blocking solution. A solution of 10% goat serum in PBS was
placed onto the slides for 30 minutes once the avidin/biotin blocking was complete. No
PBS washing step is done after the application of the goat serum solution. The primary
antibody was then added to the slides with a dilution of 1:500 with 5% goat serum in
PBS and allowed to stay on the slides overnight at 4oC. The slides must be placed in a
close container containing water to ensure the sections do not dry overnight. The slides
are then washed three times with PBS for 5 minutes each. The appropriate biotinylated
IgG was placed onto the sections for 15 minutes. For the experiments described, since
goat serum was used as the blocking buffer and the primary antibodies were mouse
based, biotinylated goat anti-mouse IgG was used. The slides were again washed with
PBS three times for 5 minutes each. Alex Fluor 633 streptavidin was diluted to a 1:400
ratio in PBS and placed onto the slides for 1 hour, protected from light during the entire
time. While still being protected from light, another set of three PBS washed for 5
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minutes were done. A DAPI solution containing 5 mg/mL was further diluted to 0.5
µL/mL and placed onto the slides for 1 minute. Two washed of PBS were done at 5
minutes and then were mounted with aqueous fluorescent mounting media and allowed
to dry for 30 minutes before imaging.
iNOS staining used a similar procedure but did not follow the streptavidin-biotin
staining method. The samples also used BSA as a serum buffer in place of goat serum
and 0.01% triton X-100 was substituted for TWEEN 20, and was allowed to only rinse
for 10 minutes. Before staining, antigen retrieval was done by placing the slides into a
solution of citrate buffer heated at 95oC for 15 minutes. The primary antibody
concentration was also increased to a 1:200 ratio as well.
4.3.7 Analytical Methods
Images of the stained sections were done on an Olympus BX51 microscope. For CD11b
and CD163 labeled tissue, the images to be analyzed were taken on the 20x objective
around the entire area of the implant. Counting cell nuclei and macrophages was done
using CellProfiler software21,22. iNOS labeled sections were taken on the 60x objective
around the implant and were quantified using pixel counting of the labeled cells and
comparing it to DAPI labeled cells.

4.4 Results and Discussion
4.4.1 Polymer Functional Group Quantification
Both materials had their functionality quantified as each reaction step progressed from
their starting synthesized materials (aminated PVC, HPAMAM) to the NAP attached
molecules (NAP-PVC, NAP-HPAMAM) to their final nitrosated product (SNAP-PVC,
SNAP-HPAMAM). The primary amine sites were quantified by reacting 3-(2-(furoyl)
quinoline-2-carboxaldehyde (FQ) to form a fluorescent product excited at 480 nm with
an emission maxima at 590 nm. NAP-thiolactone is able to covalently link to primary
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amine sites through a ring opening aminolysis mechanism. The attachment to these sites
was quantified through Ellman’s test for free thiols. After nitrosation, the NO capacity
of the two materials were tested through tri-iodide reduction. Table 4.1 shows the
quantification results of the functional groups tested which was also described in
previous chapters.
Table 4.1. Quantification of important functional groups and NO capacity of SNAPPVC and SNAP-HPAMAM as each reaction step progresses.It is important to recognize
the potential NO load amounts depending on amount of primary amine sites in a
material. Although attaching NAP-thiolactone to every primary amine functional group
is difficult, seeing the efficiency gives insight to the material kinetics. The low
attachment to HPAMAM is most likely due to a large amount of steric hindrance as the
material is a large network of multiple sized chains while the amines on the backbone of
the PVC chains are most likely spread out and in fewer number.

Primary Amines

Thiols (µmol/mg)

(µmol/mg)

Nitric Oxide
Capacity
(µmol/mg)

SNAP-PVC

0.201±0.013

0.153±0.009

0.0392 ±0.004

SNAP-HPAMAM

4.48±0.22

2.74±0.30

1.90±0.12

4.4.2 NO Release Profile
10 mm diameter films were tested for passive NO release by placing them inside
stirring PBS solutions at 37oC. The initial NO release was recorded over a set amount of
time to give an insight into the distinct release profile of the two NO releasing materials
when in contact with PBS. The polymer films were then placed inside an incubator at
37oC in PBS when not recording the NO release. Films were then taken out and tested
again periodically to observe if the polymers were still passively releasing NO. The
schematic for how the polymer layered system functions is shown in Figure 4.1.
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Ion diffusion

NO release
PVC
SNAP based polymer
PVC

Figure 4.1. Layered polymer schematic for passive NO release when implanted
subcutaneously. Since it is difficult to use the light triggering mechanisms normally
seen with SNAP based materials, using ion and heat mediated release are the most
convenient mechanisms for passive in vivo release. Due to PVC’s affinity for ion
permeability, the SNAP functional groups are able to release a substantial amount of
NO when placed in physiological conditions.

Figures 4.2 and 4.3 show the NO release profiles of the two materials under
physiological conditions. Comparing the two polymers’ NO release profiles show
SNAP-PVC exhausting most of its passive NO release over a short period of time while
SNAP-HPAMAM PVC sustains a higher NO release much longer. This is due to the
higher capacity that is seen in the SNAP-HPAMAM material. Its encapsulation within
the PVC matrix to prevent leeching also plays a large role in its persistent NO release.
Having these two types of NO release profiles to examine in vivo is important as it can
give insight into the future developments of long lasting subcutaneous NO releasing
materials. If the shorter term, lower NO release from SNAP-PVC was to perform well,
it would demonstrate the importance of having the presence of trace amounts of NO
during the acute inflammatory stages in response to a hydrophobic implant. The SNAPHPAMAM PVC also releases a majority of its NO during the acute inflammation stage,
but would have the potential NO storage to affect the transition into the chronic
inflammation stage. Care was taken to make sure too much NO was not being released
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as large amounts of NO can trigger apoptotic events with the cells in the surrounding
implanted tissue.

Figure 4.2. NO release profile of SNAP-PVC in PBS at 37oC.The release profile of
SNAP-PVC was very minimal compared to other NO generating materials that have
been implanted. Compared to the material’s release when using external triggers like
light or metal ions, the passive release does not trigger NO release at a fairly high level
for a long time.
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Figure 4.3. NO release profile of SNAP-HPAMAM PVC in PBS at 37oC.Compared to
the NO release from SNAP-PVC, SNAP-HPAMAM PVC demonstrated a much larger
NO release over a longer period of time. This allows the comparison of two distinct NO
release profiles in vivo.

4.4.3 Masson’s Trichrome Analysis
Fibrous encapsulation thickness was recorded for the 15 day implanted NO releasing
and control PVC samples and is shown in Figure 4.4. Encapsulation was quantified
across 8 tissue sections from 4 different rats for each material. Only the dense,
organized collagen at the implant-tissue interface was considered for measuring the
thickness of the encapsulation while the loose, disorganized collagen seen away from
the interface was disregarded. NO’s effect on fibrous encapsulation showed a large
reduction in thickness for the 15 day implants for both SNAP-PVC and SNAP91

HPAMAM PVC when compared to controls. The collagen was also much more distinct
in the control samples as seen in panels A and D of Figure 4.4. The individual collagen
fibrils are much more developed and easier to identify than the collagen around the NO
releasing implants.

Figure 4.4. Trichrome analysis of 15 day subcutaneously implanted materials. Panels
A, B, and C represent 200x images of PVC, SNAP-PVC, and SNAP-HPAMAM PVC
implants respectively. Panels D, E, and F represent 600x images of PVC, SNAP-PVC,
and SNAP-HPAMAM PVC implants respectively. The fibrous encapsulation thickness
(yellow arrows) were measured from the implant location (red star) to the area of
disorganized extracellular matrix.
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Figure 4.5. Fibrous encapsulation thickness data for PVC, SNAP-PVC, and SNAPHPAMAM PVC for 15 day implants. A dramatic reduction in the fibrosis response was
seen in the NO releasing implants compared to the control PVC samples. Using
α = 0.05, a significant difference in encapsulation thickness was seen for both SNAPPVC and SNAP-HPAMAM PVC when compared to PVC (p = 0.0128 and p = 0.0004
respectively).
4.4.4 Toluidine Blue Analysis
Mast cells play an important role in the inflammatory response as they release
histamine, serotonin, along with other cytokines that recruit macrophage recruitment to
a wound site23. The toluidine blue stained images are able to show degranulated mast
cells versus quiescent mast cells. NO has been shown to help modulate the rate of
degranulation in mast cells which can further prevent unwanted inflammatory cells
from approaching an implant area24. This was demonstrated in the toluidine blue stains
which showed a greater quantity of degranulated mast cells in control PVC when
compared to the SNAP-PVC and SNAP-HPAMAM PVC 1 day implants. For the 15
day implants, there was not a large difference between the numbers of mast cells across
all of the samples. This could be due to the NO reservoir being exhausted from both of
the NO donating polymers.
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Figure 4.6. Difference between active and inactive mast cells Mast cells are labeled
purple and are determined inactive (left) when they are granulated and active (right) as
the degranulation begins to occur. Although all samples showed signs of degranulated
mast cells, the NO releasing implants had the most inactive mast cell population, which
was especially seen in the 1 day implants.

4.4.5 Hematoxylin and Eosin Analysis
Observing the H&E images shows a large range of different cell types present in the
one day implants. As seen with acute inflammation, a large population of neutrophils
and monocytes have migrated to the implant site along with the presence of eosinophils
in the 1 day implants (not shown). The control PVC implants showed higher infiltration
of cells to the implant area when compared to the NO releasing implants. This result
correlates to the quantity of mast cell degranulation between the materials. It becomes
much easier for inflammatory cells to migrate to a wound site the greater the mast cell
activity.
The beginning stages of fibrosis can also be seen in the 15 day implants as chronic
inflammation begins to persist. This is seen especially in the control polymer implants.
Compared to the control, the NO releasing polymers show a much more resolved tissue
area around the interface. Control PVC also displays an increase of inflammatory cells
at the implant-tissue interface and the beginning stages of fibrosis is expressed more
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prominently. The SNAP-HPAMAM PVC implant interface has little to no
inflammatory cells on the implant-tissue interface to the same degree as control PVC
implants.

Figure 4.7. H&E analysis of 15 day subcutaneously implanted materials. Panels A, B,
and C represent the 200x images of PVC, SNAP-PVC, and SNAP-HPAMAM PVC
respectively. The 600x images are then shown in panels D, E, and F for PVC, SNAPPVC, and SNAP-HPAMAM PVC respectively. The green arrows in panel D show the
presence of foreign body giant cells at the tissue-implant interface. Red stars indicate
the implant locations.

4.4.6 Macrophage Immunofluorescence
Quantification of the number and phenotype of macrophages was done around the
implantation site. Total number of granulocytes like neutrophils, monocytes, and
macrophages were identified using CD11b while M1 macrophages were specifically
identified using iNOS antibodies. CD163 was used to quantify and locate M2
macrophage activity around the implants. All quantification data was done for the 15
day implants only. High expression of CD11b and iNOS in cells has been proven to be
an indication of pro-inflammatory M1 macrophages25. CD11b expression also directly
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relates to the release of pro-inflammatory cytokines, where high expression has
demonstrated a release of TNF-α and IL-1β26. For any implantable device, the presence
of M2 macrophages is highly preferred as they mediate and control inflammation along
with tissue remodeling while the presence of the M1 phenotype encourage chronic
inflammation. M2 macrophages also help remodel tissues by producing certain MMPs
and produce VEGF to promote blood vessel fusion and formation27.
A noticeable difference between the two macrophage phenotypes and total number of
granulocytes was seen between the NO releasing implants and control implants. Along
with the quantity present around the implant interface, the location of the specific
macrophage phenotypes was also observed. For the 15 day PVC control implants,
iNOS+ macrophages have a high density around the majority of the polymer-tissue
interface area while CD163+ macrophages seem to be much less frequent overall. The
15 day NO releasing PVC implanted materials showed a much lower concentration of
iNOS+ macrophages near the implant. The aggregation of macrophages at the interface
was less consistent than the aggregation around the control PVC sections. The presence
of CD163+macrophages in the NO releasing PVC was also more prevalent overall when
compared to the control PVC. When observing the iNOS stained sections for the NO
releasing polymer implants, there are cells at the implant-tissue interface that stain
negatively for iNOS while control sections have a uniform labeling of iNOS+ cells
around the majority of the interface. This signifies a possible switch in phenotype of the
migrating M1 macrophages due to the release of NO. There is also the possibility that
they are still M1 macrophages but are not as active.
There is also more polymer fragmentation present in the control PVC implants than the
NO releasing implants. iNOS and CD11b images show a high density of macrophages
surrounding these polymer fragments within the tissues indicating frustrated
phagocytosis. The SNAP-PVC showed a minor amount of polymer fragmentation
compared to the control PVC, while the SNAP-HPAMAM PVC showed none at all.
NO in high enough concentration has the ability to decrease the amount of chronic
inflammatory cytokine release from macrophages which then lowers the recruitment of
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macrophages to the material interface28. In the absence of NO, these cytokines are
upregulated to allow the migration of more macrophages to the implantation site along
with macrophage fusion. Eventually this fusion of macrophages leads to the formation
of foreign body giant cells (FBGCs), which will release harmful degradative enzymes to
attempt to break apart the polymer29-30. As seen in the H&E stain in Figure 4.7, FBGCs
and the total number of cells at the interface are much higher in control PVC.
4.4.7 Macrophage Phenotype Quantification
Observations were made on the images taken with respect to macrophage number and
phenotype based on NO release. Images were taken at 200x magnification around the
implant area for both CD11b+ and CD163+ sections and were counted using CellProfiler
software. An independent samples student t-test was then done to compare the presence
of CD11b+ and CD163+ cells in control PVC implants to SNAP-PVC and SNAPHPAMAM PVC implants. Quantifying the iNOS+ cells proved to be more difficult, as
iNOS stains for cytoplasmic features within macrophages while CD11b and CD163
both stain for membrane bound proteins, which are much easier for cell counting
programs to identify. Pixel counting was used instead to quantify the iNOS activity
within the tissue sections using ImageJ and Adobe Photoshop. The positive iNOS pixels
in the green channel were compared to the DAPI pixel count in the blue channel and the
ratio between the two was used to compare the overall iNOS activity around the implant
sites under 600x magnification.
For the 15 day implants, a no significant difference was seen in CD11b+ or CD163+ cells
when comparing control PVC implants when to both the SNAP-PVC and SNAPHPAMAM PVC implants. Although there was no significant difference, there is an
observable trend in a decrease of CD11b+ cells with the increased in NO delivery from
the SNAP-PVC and SNAP-HPAMAM PVC along with a slightly increased trend in
CD163+ cells for the SNAP-HPAMAM PVC. This increase in M2 macrophage
population coincides with the fact that the implant area contained the lowest population
of granulocytes and M1 macrophages, demonstrating their ability to control and
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decrease the inflammatory response to a wound site or implant. By referring back to
Figure 4.7, panel F, the consequences of a higher population of CD163+ cells can be
seen from the H&E stain. There is much less matrix formation along with higher
vasculogenesis around the implant area, which could be caused from the secretion of
VEGF from active M2 macrophages. This trend also been proven previously using
CD31 staining to demonstrate the angiogenesis that occurs around NO releasing
subcutaneous implanted materials13.
The one day implants showed nearly identical amounts of cells marked with both
CD11b+and CD163 for all polymers (not shown). The presence of CD11b+ cells at the
initial stages of implantation are expected to be the same as NO’s main effect is to
hinder pro-inflammatory cytokines that further the propagation and recruitment of
additional macrophages. The CD11b+ cells are most likely neutrophils, monocytes, and
eosinophils along with the initial differentiating macrophages for the 1 day implants.
This could also factor in to the lack of statistical difference between the materials as the
stages of acute inflammation is relatively consistent and necessary part of the wound
healing process.
For quantification of iNOS+ cells around the implant, 600x images were taken around
the tissue-implant interface and a pixel count ratio between iNOS stained features
(green) and DAPI labeled cells (blue) was done. Since iNOS is labeled within the
cytoplasm of macrophages, individual counting would prove to be difficult. Active
macrophages will display a strong iNOS signal that can be accurately quantified. To
observe the difference in signal, RAW 264.7 passage 13 murine macrophages were
treated with LPS and stained with iNOS and is shown in Figure 4.8. The LPS treated
macrophages simulate their morphology when active. When comparing the
macrophages at the interface in PVC control implants to the NO releasing implants,
there is a distinct difference in the macrophage morphology and is shown in Figure 4.9.
The PVC control shows a very similar active phenotype similar to the LPS treated
macrophages. This extreme activity is also seen around polymer fragmentation that
occurs which is shown in Figure 4.10. The large standard deviations seen in the PVC
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quantification is due to these fragmentation events that occurred in two of the PVC
implants, which then greatly increased the presence of iNOS+ cells around the implant
area. SNAP-PVC still demonstrated a region of active M1 macrophages at the interface,
but the overall activity of them was much less than the PVC interface. When comparing
the iNOS/DAPI ratio between PVC and SNAP-PVC, there was no significant difference
seen. Even with less active macrophages at the interface, there were still a large number
around the tissue area that stained positive for iNOS. This demonstrates that the passive
NO release from SNAP-PVC was not enough to hold off the overall aggressive
macrophage inflammation to the implant. SNAP-HPAMAM PVC implants
demonstrated a less active interface area along with a low macrophage count in the
surrounding tissue. In this case, a significant reduction of the iNOS/DAPI ratio was
seen when comparing SNAP-HPAMAM to PVC.

Figure 4.8. Cell culture of RAW 264.7 murine macrophages stained with iNOS at
600x.LPS treated (right image) and non-LPS treated (left image) demonstrate the
difference in iNOS staining activity. More active macrophages have a much larger
cytoplasm filled with iNOS enzymes.
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Figure 4.9. Immunofluorescence of iNOS+ cells (green) around 15 day implants.PVC
control (top) displayed very active macrophages, especially at the implant interface.
SNAP-PVC (middle) also showed a lot of activity, but with smaller iNOS+ cytoplasmic
features. SNAP-HPAMAM PVC (bottom) had the lowest amount of iNOS activity from
macrophages, and only showed aggregation of macrophages at the interface in rare
occaisions. SNAP-HPAMAM stained macrophages were mostly seen away from the
interface area. A signfiicant difference in the ratio of iNOS/DAPI was seen when
comparing PVC to SNAP-HPAMAM PVC (p = 0.0312), but no significant difference
was seen between SNAP-PVC and PVC (p = 0.2897). Red stars indicate the
implantation area. Red stars denote the implant location.
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Figure 4.10. Inflammatory response to polymer fragments seen in 15 day PVC
implants.The aggregation of iNOS labeled cells (green) show the consequences of the
increased, harsh inflammatory response to the control PVC implants as these tissue
sections showed the most polymer fragmentation (red star). Image was taken at 600x
magnification.
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Figure 4.11. Immunofluorescence and analysis of cell nuclei, CD11b, and CD163
marked cells for 15 day implants.Aggressive and inflammation inducing cells were
marked with CD11b (red) for PVC (A), SNAP-PVC (B), and SNAP-HPAMAM PVC
(C) while cell nuclei were stained with DAPI (blue). Anti-inflammatory, M2
macrophages were marked with CD163 (red) for PVC (D), SNAP-PVC (E), and SNAPHPAMAM PVC (F). White stars indicate the locations of the implant. Quantification of
the tissue around the implants shows no significant reduction in CD11b+ or CD163+
cells for both NO releasing implants, but a trend was observed in the quantification for
CD11b (G) to demonstrate a reduction in the overall cell count. CD163+ macrophages
also saw a slight increase in quantity with increased exogenous NO delivery (H) when
compared to control PVC. Total cell count was also reduced around the SNAPHPAMAM implant compared to PVC (I). An alpha level of 0.05 was used for all
statistical testing. Error bars represent one standard deviation.
The results from these experiments demonstrate slightly different results from in vitro
experiments that were done in the past. Human mononuclear cells have been shown to
express pro-inflammatory cytokines such as TNF and IL-1 when incubated with 100
102

uM levels of SNAP NO donors, suggesting a phenotypical switch to an M1 state if
concentrations are high enough31. However, these levels of NO were not released from
the implanted materials over the time periods that are being described. The in vitro
studies of utilizing NO donors in this manner implies all of the NO is being
administered at once. Using an NO donating material that is able to keep a lower, more
steady flux of NO over a period of time would elicit a different response. This suggests
a different possible mechanism for migrating blood monocytes towards a region of
more controlled, lower NO release rather than an entire saturated environment of SNAP
NO donors.

4.5 Conclusion
Two different NO releasing PVC based polymers that released different total amounts
of NO were able to elicit different immune responses compared to control PVC based
on the level and duration of NO being emitted into the surrounding tissue. While
SNAP-PVC and SNAP-HPAMAM PVC implants were not able to significantly reduce
the amount CD11b+ and CD163+ cells, there was a general trend occurring for these cell
types with the two specific NO release profiles. More rats would need to be tested in
future studies to further verify these trends. There was a significant reduction in the
fibrous encapsulation area around the implants for both NO releasing polymers, proving
that even small amounts of exogenous NO release is capable of reducing fibrosis to
implants. The passive NO release from SNAP-PVC was too low for the implantation
duration seen to give impressive in vivo results when observing the overall presence of
iNOS around the implants. Another external factor would have to be used to trigger the
NO release from the SNAP-PVC polymer to elicit a more favorable anti-inflammatory
response. However, SNAP-HPAMAM PVC was able to see a significant reduction in
iNOS+ cell activity, demonstrating that the proper NO flux is able to lower this type of
aggressive macrophage interaction. Future studies could be done using an even higher
NO capacity polymer film utilizing SNAP-HPAMAM blends over longer periods of
time.
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Chapter 5 : Nitric Oxide Releasing Materials as
Potential Antivirals
5.1 Introduction
The applications of NO as an antibacterial has been demonstrated from previous
controlled NO releasing materials, and is the primary method for macrophages to kill
foreign bacteria around a wound site through the formation of peroxynitrites1. This
same mechanism can be applied to viruses as peroxynitrite byproducts will be able to
react with viral proteins in the same manner. NO has already been proven to be a potent
antiviral molecule, but the exact dosage over time has never been properly tested2. In
past studies, an NO donor such as SNAP is added into solution at high concentrations to
interact with the suspended viruses. This strategy has shown to inhibit virus replication
by targeting viral protease in Coxsackievirus3. Specifically, NO was able to nitrosate the
active cysteine sites on the viral protease enzymes, which reduced the overall
functionality of the virus. Dengue virus was also observed in a separate study where the
addition of SNAP was able to suppress viral RNA synthesis4. SNAP was added to
culture medium at concentrations of 150 µm, which was replenished every 4 hours up to
8 hours after infection and then incubated for 40 hours.
Using NO as an antiviral poses the question of how it exactly is interacting with the
viral structure as a whole – whether it is interacting with the viral envelope, the protein
capsid, enzymatic molecules within the virus, or the actual DNA/RNA structure itself.
NO as a radical molecule is capable of reacting with multiple types of functional groups
to slightly alter these important structures of viruses as a method for disabling their
ability to attach to cells and inject their genetic material to be replicated. NO has also
been shown to alter DNA/RNA structures through nitrosative deamination of base
pairs5. Figure 5.1 shows how an NO donating material can affect a virus from normally
functioning and replicating. This could be another mechanism for which viruses become
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deactivated after being exposed to NO. As there are multiple different classes of
viruses, how NO interacts with each one of them is bound to be different.
NO Donating Material

NO

NO + O2

ONOO

-

Virus

-Nitrosative deamination
-Oxidative damage
Figure 5.1. Mechanism for DNA damage within viral species from an NO donating
material.If NO does not react with the protein capsid layer, its peroxynitrite byproduct
will be able to diffuse through and react with the DNA structures within. This leads to
deamination of the base pairs in the DNA structure and causes oxidative damage,
causing the virus to become unable to infect other cells.
The investigation of using NO as a potential antiviral was done through using controlled
doses of NO over specific time intervals with SNAP-PDMS and SNAP-PVC. This gave
a preliminary insight into how much NO is required to inactivate viruses from
transfecting other vulnerable cells. The two viruses that were used were porcine
parvovirus (PPV) and sindbis virus (SINV). PPV is a single stranded DNA (ssDNA)
109

classified virus with no viral envelope while SINV is a single stranded RNA (ssRNA)
classified virus which contains a viral envelope.
In these preliminary studies, SNAP-PDMS and SNAP-PVC were used as the material to
deliver controlled amounts of NO over the course of 1 and 2 hours to PPV and SINV
virus particles suspended in PBS. Once a threshold for the amount of NO over a specific
time period can be identified, further experimenting can be done using higher doses
over even shorter periods of time. For practical purposes in an environment where a
virus is airborn, an NO releasing air filter could be developed to eliminate or deactivate
an important viral function. This situation could require a high amount of NO being
delivered at the interface of the filter, which the SNAP-HPAMAM material described in
chapter 3 is more than capable of delivering. Shorter time studies can be done in the
future using extreme amounts of NO delivery over the course of a few seconds using
SNAP-HPAMAM once the NO threshold for deactivating a virus is discovered.

5.2 Experimental Details
5.2.1 Materials
The materials used to synthesize SNAP-PDMS were Hydroxy-terminated 2000 cSt
polydimethylsiloxane (PDMS) was purchased from Gelest, Inc. (Morrisville, PA, USA).
3-Aminopropyl trimethyoxysilane, dibutyltin dilaurate, cyclam, and toluene were
obtained from Sigma-Aldrich Co. (St. Louis, MO, USA). Tert-butyl nitrite (90%
technical grade) was purchased from Acros Organics (Geel, Belgium).
5.2.2 Synthesis of SNAP-PDMS
The synthesis procedure followed a protocol described previously6. 1.6 g of the
hydroxyl-terminated PDMS is first dissolved in 8 mL of toluene. 0.3 g of 3aminopropyl trimethoxysilane and 2.4 mg of dibutyltin dilaurate are then added to the
solution and it was allowed to stir overnight to crosslink. This exposes primary amine
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groups that can then be reacted with NAP-thiolactone. 50 mg of NAP-thiolactone is
mixed with 2 mL of the crosslinked PDMS to form NAP-PDMS after allowing to stir
for 24 hours. The newly exposed thiol group can then be reacted with t-butyl nitrite as is
mentioned in the previous chapters.
5.2.3 Experimental design
A breadboard containing six blue, 470 nm LEDs connected to 130 Ω resistors was
constructed. PVC pipe (15 mm OD, 12 mm ID) was cut into 30 mm lengths and placed
around the mounted LEDs. Set screws were placed 10 mm from the top of the PVC
sections for the samples to rest on. SNAP-PVC and SNAP-PDMS were used as the NO
releasing polymers for testing. The polymer samples were cast into films in the bottom
of 2 mL glass vials. Due to the shape of the bottom of the vials, multiple layers were
cast to ensure the final polymer product does not dry in a concave shape. A final layer
of RTV-3140 (medical grade silicone rubber) was placed on top of the SNAP-PDMS
layer to ensure no unwanted ion diffusion occurs while a layer of cellulose acetate was
cast on the SNAP-PVC films.
For testing, the viral solutions were suspended in PBS and placed into the vials
containing the bottom coated polymers. The LEDs were then turned on to trigger NO
release from the polymer films into the viral solution for 1 and 2 hours. After the NO
treatment, the viral solutions were transferred into microcentrifuge tubes and
refrigerated until they were used for MTT assay analysis. The cells to be infected with
the viral solutions were PK13 (ATCC CRL-6489) pig epithelial cells.
5.2.4 Nitric oxide measurements
NO detection was recorded in real time from the nitric oxide analyzer for multiple trials
using the same setup that was being tested in the actual virus trials to accurately
demonstrate the NO diffusion from the polymer films to the viruses suspended in PBS.
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This was done for both 1 and 2 hour trials. Ambient light testing was also done for
control SNAP-PDMS samples where the LED was turned off.
5.2.5 Virus activity measurements
After being exposed to NO, cells were then administered with the treated virus solutions
in culture. A live/dead assessment was then done on the treated and untreated cell
cultures using an MTT assay.
Log reduction value (LRV) of the solution was calculated to determine the percentage
of virus particles able to still infect cells. Complete inactivation of the virus (99.99%)
was calculated at an LRV of 4.

5.3 Results and Discussion
5.3.1 Nitric oxide profiles
Identical polymers were cast into the 2 mL vials and were tested for NO release using
the same setup used in the viral NO testing. The polymers were tested at the same time
the virus samples were being tested to ensure the release profiles were as similar as
possible.
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Figure 5.2. NO release profile of SNAP-PDMS over 2 hours when LED activated. The
total amount of NO released over the 2 hour period was 0.270 µmol, and was proven to
be enough NO to deactivate PPV replication.

Figure 5.3. NO release profile of SNAP-PDMS passively with no LED over 2 hours.
The amount of NO in the trials with the LED off was done in the scenario where there
was viral removal with extremely low amounts of NO. Later experiments demonstrated
that this low, passive amount of NO release had no effect on the viruses.
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Figure 5.4. NO release profile from SNAP-PVC over a 2 hour time period. The release
seen in the SNAP-PVC compounds was also shown to prevent PPV from infecting
cultured cells.
5.3.2 Virus Functionality
Exposure to NO at both 1 and 2 hour release demonstrated complete deactivation of the
viruses for SNAP-PVC and SNAP-PDMS. Comparing these preliminary results to other
studies that have been done in the past show that the amount of SNAP that was
previously being put into viral solutions were much higher than what is needed.
Although the viruses were unable to infect cells in culture after exposure to NO, a lower
limit still needs to be discovered. Once this lower limit is determined, a more precise
NO releasing material design can be made using materials like SNAP-HPAMAM.
Depending on the amount of NO required over a period of time, a material can be
tailored to have a certain amount of SNAP-HPAMAM blended in it to ensure the
viruses are exposed to that level.
5.3.3 Preliminary Data Collection
SNAP-PVC was used as the first NO donating material to attempt to deactivate PPV in
solution. The first trials that were done showed promising results of high viral removal
after being exposed to both 1 and 2 hours of LED triggered SNAP-PVC. However, after
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further investigation, it was shown that the high NO release was actually causing the
formation of nitric acid in the viral solutions, which drastically decreased the pH. Even
without the LED turned on, passive SNAP-PVC release from ion diffusion was causing
a change in pH.

Log Removal for NO PPV trial
5.00

Log removal

4.00

Log removal

3.00
2.00
1.00
0.00

6Log 1hr 6Log 2hr 4Log 1 hr 4Log 2hr PVC with NO Sans
LED
LED

Figure 5.5. PPV removal using SNAP-PVC as the NO releasing polymer. The LED
was turned on for 1 and 2 hour time points. Log 4 removal of the virus shows that
99.99% of the virus was deactivated or killed when administered to cell cultures, which
was demonstrated for SNAP-PVC when the LED was on and off. The removal with the
LED off was due to the pH change seen from surface nitrites on the SNAP-PVC
diffusing into solution to form nitric acid. Control PVC with the LED on and off
showed no removal of the virus.
To solve the issue of passive pH change causing virus deactivation, the SNAP-PVC
films were thoroughly rinsed with DI water before being tested with the viral solutions.
This washes off any surface nitrites that may have lingered from the t-butyl nitrite
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nitrosation step that end up diffusing into solution causing the formation of nitric acid.
After washing, the SNAP-PVC was then tested for NO release and ensured no pH
change occurred before being tested. Tests proved 99.99% removal of PPV with the
administration of NO over a 1 hour and 2 hour period. Control PVC and SNAP-PVC
with the LED turned off demonstrated no viral inactivation. No pH change was
observed for any of the trials.
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Figure 5.6. PPV removal using pre-washed SNAP-PVC as the NO releasing polymer.
The LED was turned on for 1 and 2 hour time points. Log 4 removal of the virus shows
that 99.99% of the virus was deactivated or killed when administered to cell cultures.
Control PVC and SNAP-PVC with the LED off showed no removal of the virus. There
was no pH change as well for the trials, proving NO was causing the removal.

5.4 Conclusion
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The results presented show the potential of NO as a possible antiviral tool for future
materials. The experiments described demonstrate how with enough time, a precise
measurement on how much NO over a certain amount of time is needed to deactivate
the infection potential of viral species. After this dose of NO is determined, it can be
applied to real life situations where the spread of airborn viruses in closed locations is
problematic.
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Chapter 6 : Concluding Remarks and Future Direction
6.1 Summary of Findings
The utilization of NO is still a growing field and more applications are still being
discovered. By understanding how our body synthesizes and releases NO broadens the
potential for NO donating materials to mimic some of these beneficial effects. Whether
it is killing off bacteria through the iNOS synthetic route of macrophages or allowing
our vasculature to maintain a healthy blood pressure through the production of NO from
endothelial cells, NO donors will strongly impact the medical field.
The synthesis of a covalent bound NO donor to PVC to create a SNAP-PVC compound
opens up a variety of opportunities for how PVC is used in the medical field. Being one
of the most commonly used polymers in the medical industry, there is huge potential for
replacing common PVC based devices while expanding its uses into other blood and
tissue contacting devices such as catheters.
Using a similar hyperbranched molecular synthesis approach that is seen in dendrimers,
a hyperbranched SNAP based polyamidoamine was successfully synthesized and shown
to be extremely stable when isolated as a solid. The synthesized SNAP-HPAMAM is
one of the highest capacity NO donating materials by mass when compared to the
variety of other NO donating materials. Although highly branched NO releasing
dendrimers have been synthesized previously, the amount of cost and time it takes to
reach that level is extreme. Using hyperbranched chemistry greatly cuts down on both
of these issues while still maintaining a high NO capacity.
These two materials were then able to demonstrate their capabilities of using the
beneficial effects of NO by warding off unwanted inflammation when implanted
subcutaneously. The PVC blended with SNAP-HPAMAM ended up performing better
than SNAP-PVC due to its NO releasing longevity. Overall, both materials had less
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aggressive macrophage infiltration, less fibrous encapsulation of the implant, and less
FBGC fusion occurrences at the tissue-implant interface.
Preliminary findings of NO’s effect on viruses proved to be very promising. The setup
being used is more effective than what has previously been done when investigating the
concentrations needed to deactivate viral compounds. Over a period of 1 and 2 hours,
both SNAP-PVC and SNAP-PDMS polymers were able to deliver enough NO to obtain
an LRV of 4. The method of having a polymeric system releasing NO into solution is a
much more precise method than simply adding SNAP into a solution containing your
target virus.

6.2 Future directions
While covalently binding SNAP to the backbone of PVC was successful, its overall
capacity was lower than expected. This was due to the complications with attaching a
difunctional compound to the backbone of a polymer. In this scenario, crosslinking is
virtually unavoidable, which limits the loading capacity potential to PVC. To improve
on this, a different strategy will need to be implemented. One possible suggestion is to
use a diamino compound that has one of the primary amine groups protected. Once the
free primary amine group is attached to the polymer backbone, it will be unable to
crosslink with other polymer chains. The material can then be deprotected, exposing a
primary amine group for NAP-thiolactone to attach to. This could greatly increase the
NO capacity potential, but would also increase the cost to synthesize.
Although the NO capacity in SNAP-HPAMAM was shown to be very high, there is still
room for improvement to increase it. One of the major issues seen during the synthesis
was attaching the NAP-thiolactone to the material efficiently. If this problem could be
overcome, the storage capability would increase dramatically.
Future studies for subcutaneous implants using SNAP-HPAMAM could be done where
more of the NO donor is loaded onto other types of polymers over longer periods of
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time. The study done in chapter 4 was to examine the acute to chronic inflammation
transition and NO’s role in how it can slow its progress. The amount of SNAPHPAMAM loaded into the polymer was also fairly small, as there is a risk of releasing
too much NO too quickly and causing cell necrosis which I wanted to avoid. For long
term implants that last for months, it would be interesting to see how inflammation
progresses in other hydrophobic or slow degrading polymers like PLLA.
By being able to accurately track the NO being released from a polymer film into a
solution containing a target virus, we are able to pin point the exact dosage of NO over
what period of time is necessary to deactivate viruses. This sets a new precedent for
how NO can be administered to these types of targets suspended in solution. More
insight into how NO is altering the viruses will need to be done in future studies. This
could be done by observing changes in capsid proteins using western blotting
techniques or MALDI-TOF. If the DNA or RNA structures are being altered, PCR
could be done to prove any nitrosative deamination of base pairs that could be
occurring.
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Figure A.1. Calibration curve of ATTO-TAG FQ test for amines using glycine-HCl as
a standard.
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Figure A.2. Calibration curve of Ellman’s test for thiols using cysteine as a standard.

Table A.1. CHN combustion analysis of the PVC-NH2 polymer based on its reaction
time with ethylenediamine. The table shows an increase in nitrogen content, but the
ATTO-TAG FQ results show a decreased amount of primary amine sites once it reacts
beyond 2 hours. This shows the possibility of crosslinking occurring between polymer
chains as the reaction progresses. The ideal time point was found to be 2 hours.

Sample

%N

PVC 1 hour reaction time

0.15

PVC 2 hour reaction time

0.167

PVC 4 hour reaction time

0.20
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Figure B.1. SNAP-HPAMAM blended PVC under a 470 nm LED (3V, 150Ω).
Demonstrates SNAP-HPAMAM’s ability to retain a controlled flux over a long period
of time for in vitro testing.
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Figure B.2. 1H NMR data of HPAMAM in CDCl3.
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Figure B.3. XRD of SNAP-HPAMAM. Once nitrosated either by t-butyl nitrite or
sodium nitrite, SNAP-HPAMAM displays unique crystalline features when isolated as
seen in the XRD scan.
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Appendix C

Supporting Information for Chapter 4

Figure C.1. CellProfiler example for cell nuclei (DAPI) marking. DAPI stained images
are first converted to gray scale before counting analysis begins.
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Figure C.2. CellProfiler counting analysis of DAPI stained cells. Parameters are set for
the program to declare what specifies as a cell nuclei and what is not. Even in clumped
areas where counting is difficult, the CellProfiler program is able to “declump” and
count the objects based on signal intensity.
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Table C.1. Results and analysis of CellProfiler cell nuclei counting for Figure C.2.
Displays the details given from the program when analyzing a specific image.

Threshold

0.365

# of accepted objects

1560

10th pctile diameter

7.7 pixels
13.0

Median diameter

pixels
17.9

90th pctile diameter

pixels

Area covered by objects

16.00%

Thresholding filter size

1

LoG threshold

0.4

LoG filter diameter

8

Declumping smoothing filter
size

3.4

Maxima suppression size

3.3
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Figure C.3. CD163 stained SNAP-HPAMAM PVC image before CellProfiler
processing.
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Figure C.4. CellProfiler conversion of Figure C.3 to grayscale for macrophage
counting.
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Figure C.5. CellProfiler counting and analysis of CD163 stained images. Setting
parameters for macrophage stained images proved to be more difficult as some of the
antibodies (CD163 and CD11b) mark membrane proteins. This meant that declaring the
macrophage size was dependent on how much of the surface proteins were actually
positively marked.
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Table C.2. Results and analysis of CellProfiler cell nuclei counting for Figure C.5.
Threshold

0.093

# of accepted objects

254

10th pctile diameter

7.7 pixels
10.5

Median diameter

pixels
18.9

90th pctile diameter

pixels

Area covered by objects

2.40%

Thresholding filter size

1

LoG threshold

0.4

LoG filter diameter

10

Declumping smoothing filter
size

4.7

Maxima suppression size

4.7
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SNAP-HPAMAM PVC

PVC

Figure C.6. CD68 macrophage marker for SNAP-HPAMAM PVC (left column, top
200x, bottom 600x) implanted films and PVC control (right column, top 200x, bottom
600x). Demonstrates NO’s ability in the SNAP-HPAMAM form to lower the overall
macrophage response to the implants along with lowering the cell density infiltration
surrounding the implant.
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Figure C.7. 200x image of 15 day SNAP-HPAMAM PVC section stained with CD163
(red) and CD68 (green). This visualizes the location of M2 macrophages with respect to
M1 macrophages. The M2 macrophages are closer to the adipose tissue, regulating the
inflammation and migration of subsequent macrophages to the implant site. The M1
macrophages are mainly seen at the tissue-implant interface. Implant area is labeled
with a red star.
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Supporting Information for Chapter 5

Figure D.1. Lightboard setup used for initiating NO release from vials containing
SNAP based polymers.
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Figure D.2. Description of how the LED-virus setup interacts. A three layered system
was initially used where the bottom layer (green) is the controlled NO releasing
polymer layer, the middle layer (gray) is the control polymer layer to prevent cation
diffusion into the SNAP polymer system, and the top layer (blue) is a cellulose layer to
prevent the virus particles from attaching to the polymer surface. The LED’s being used
are VAOL-5GSBY4 5GSBY4 (λ = 460nm) and will be placed approximately 16 mm
below the virus containing vial to make sure the 30 degree cone angle covers the entire
8.50 mm diameter film being cast.
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